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Overview
The main focus of this project is the impact of Deep Brain Stimulation (DBS) surgery on 
reward responsiveness in Parkinson’s disease (PD). This project aims to investigate what 
the neuropsychological effects of this surgical treatment can teach us about the 
mechanism of stimulation and its effects on the underlying neural circuits that are 
damaged in this disease.
The first part of this project aims to review the evidence on apathy in Parkinson’s 
disease. Studies published to date are discussed and critically reviewed, with reference 
to the occurrence of apathy in Parkinson’s disease and the effects of neurosurgical 
intervention on the occurrence of apathy in Parkinson’s disease.
The second part of this project aims to assess Parkinson’s disease patients who have 
undergone Deep Brain Stimulation surgery for the treatment of the motor symptoms of 
the disease. Specifically, this study aims to assess the impact of Deep Brain Stimulation 
on reward responsiveness, as measured by patient’s motor performances on a simple 
reaction time task and a card-sorting task.
The final part of this project is a critical appraisal of the research, reflecting on the 
research process; the strengths and weakness of the study, changes I would make to 
improve the study and how further research could build upon the results obtained here 
are discussed.
xi
Part 1. Literature Review
“A Review of Apathy in Parkinson’s Disease”
Abstract
Apathy is defined as a primary loss of motivation in the absence of emotional distress, 
intellectual impairment or clouding of consciousness. High rates of apathy occur in 
Parkinson’s disease (PD), with some authors suggesting that it is a core feature of the 
disease. The factors that influence the occurrence of apathy in PD are controversial, 
however some factors are consistently found to be associated with higher levels of 
apathy in this population, namely damage to the basal ganglia or frontal lobes; dopamine 
deficiency; dementia and hallucinations. The factors that do not influence the occurrence 
of apathy in PD are depression and severity of motor impairment caused by the disease. 
Deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) is a surgical technique 
used to ameliorate the aberrant motor symptoms of PD. However, as well as influencing 
motor symptoms, STN DBS has been found to have effects on cognitive, affective and 
psychosocial functioning. The effects of STN DBS on apathy are unclear, with some 
studies finding evidence of worsening and others finding improvement of apathy. 
However the factors that have been suggested to influence the occurrence of apathy in 
these patients are increased age, longer pre-operative disease duration, and more severe 
motor symptoms. The frontal-subcortical circuits are a group of five parallel neural 
pathways, connecting the basal ganglia with the frontal lobes. Due to deterioration of the 
basal ganglia in PD, these circuits have been implicated in the motor and non-motor 
symptoms of the disease, including apathy. More research is required to develop our 
understanding of the effects of stimulation on apathy in PD and the neural circuits that 
underlie it.
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Parkinson’s disease (PD) is a progressive degenerative neurological disorder resulting 
from the degeneration of the dopamine producing cells in the substantia nigra pars 
compacta, which forms part of the basal ganglia (Crossman & Neary, 2000). Apathy is 
common in PD and is one of the non-motor symptoms of the disease. In this review the 
pathophysiological model of PD, treatment approaches used and the motor and non­
motor treatment outcomes will be discussed by way of introduction to PD. The main 
focus of this paper is apathy in PD and the influence of DBS on the occurrence and 
course of apathy in PD patients. This is an area of some debate within both academic 
and clinical arenas, as there is much conflicting evidence as to the nature of apathy in 
these populations. However, there is consistent evidence regarding the negative impact 
of apathy in PD, both for patients who have undergone surgical treatment and those who 
have not, and for their families. This highlights the need for further study and reflection 
upon the impact of treatments, including deep brain stimulation surgery, on apathy, as 
this the potential impact of surgical intervention may constitute an ethical consideration 
on the part of clinicians and an additional factor in the decision to undergo surgery for 
patients and families. The current literature on apathy in PD will be discussed in relation 
to its prevalence and presentation, the relationship of apathy to other PD symptoms, and 
the neural pathways common to both apathy and the motor symptoms of PD. This leads 
to the main focus and research questions of this review; “What factors influence the 
development of apathy in PD?” and “Does deep brain stimulation of the subthalamic 
nucleus influence apathy in PD?”.
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Research method
For the purposes of this review, a structured Pubmed search was performed on articles 
up to May 2008. The following key words were used; apathy; Parkinson’s disease; 
subthalamic nucleus; deep brain stimulation; treatment; function. These studies were 
reviewed by one investigator (AH).
1.0 Parkinson’s disease
The basal ganglia are a group of subcortical nuclei; the striatum is the anatomical term 
for the caudate nucleus and putamen, which are the input areas of the basal ganglia, 
while the internal segment of the globus pallidus and the substantia nigra pars reticulata 
(SNr) are the output areas of the basal ganglia (Crossman & Neary, 2000). Figure 1(a) 
illustrates the location of the striatum and related structures. When these areas are 
damaged they give rise to a group of disorders, termed basal ganglia disorders 
(Crossman & Neary, 2000). Parkinson’s disease (PD) is a degenerative neurological 
disorder resulting from the degeneration of dopamine producing cells in the Substantia 
Nigra pars compacta (SNc) (Brown & Jahanshahi, 1991). The major symptoms of PD 
include tremor, rigidity, bradykinesia (slowness of movement) and postural abnormality. 
Other common symptoms include balance and walking problems, akinesia (poverty of 
movement) micrographia (reduced size of hand-writing), dysphonia (reduced vocal 
volume), masked faces and fatigue (Gibb & Lees, 1989). Prevalence rates of PD can 
vary widely according to diagnostic criteria and other inclusion factors, ranging from 
approximately 10 in 100,000 to 405 in 100,000 (Korell & Tanner, 2005). Risk factors 
for PD have been identified, including increasing age and male gender; while protective
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factors include smoking and the use of non-steroidal anti-inflammatory drugs (ibid).
Figure 1(a). The Striatum and related structures (Bear, Connors & Paradiso, 
2001)
1.1 The Pathophysiological Model of PD
1.1.1 The Frontal-subcortical circuits
The symptoms of PD result from of the depletion of the dopamine pathways of the pars 
compacta subdivision of the substantia nigra (Crossman & Neary, 2000). As a result, the 
balance of activity in the direct and indirect pathways of the frontal cortex are altered 
leading to the inhibition of cortical motor areas resulting in the manifestation of 
bradykinesia and akinesia in PD (Alexander, De Long & Strick, 1986). The motor 
circuit involved in PD is one of the five, comprising the frontal-subcortical circuits 
between discrete areas of the striatum and the distinct parts of the frontal cortices. The 
motor circuit mediates motor control, while the remaining four circuits mediate 
oculomotor control (oculomotor circuit), executive function (dorsolateral prefrontal
5
circuit), emotion and social behaviour (lateral orbitofrontal) and motivation (anterior 
cingulate circuit) (Alexander et al, 1986). Figure 1(b) illustrates these circuits.
Figure 1(b). The “Motor”, “Executive”, “Emotional and “Motivational” circuits
respectively, from Alexander, De Long & Stride’s (1986) Model of the frontal- 
subcortical circuits
DL: Dorsolateral; DM: Dorsomedial; VL: ventrolateral; VA: ventroanterior; VM: ventromedial 
1.1.2 The Subthalamic Nucleus
The Subthalamic Nucleus (STN) is a group of cells that, along with the Globus Pallidus 
externa (GPe), forms the indirect pathway between the basal ganglia and frontal cortex, 
and alters the output of the basal ganglia to the cortex (Alexander et al, 1986). In the 
healthy basal ganglia projections from the striatum inhibit the lateral pallidum, which in 
turn disinhibit the STN, resulting in the discharge of subthalamic neurons and the 
activation of medial pallidal and nigral neurons and the inhibition of thalamic and 
cortical neurons (Crossman & Neary, 2000). This activity, therefore, leads to the 
inhibition of unwanted movements in the healthy basal ganglia. Figure 1(c) illustrates
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the pathophysiological model of Parkinson’s disease in comparison with healthy 
function.
In PD there is excessive excitatory drive from the Subthalamic nucleus (STN) to the 
Globus Pallidus interna (GPi), coupled with reduced inhibitory input from the Globus 
Pallidus externa (Gpe) to the GPi, the result of which is excessive inhibitory outflow 
from the GPi to the ventral thalamus, leading to the under-activation of the frontal 
cortical areas (Cummings, 1993). Evidence for this frontal underactivation is provided 
by imaging studies in PD (Jahanshahi et al, 1995; Playford et al, 1991). The overactive 
STN and GPi and the alteration of balance of activity in the direct and indirect pathways 
are associated with bradykensia and akinesia as well as dyskinesias (involuntary 
movements) in PD (Crossman & Neary, 2000).
Figure 1(c). The pathophysiological model of Parkinson’s disease compared with healthy
function (Cenci, 2007). The basal-ganglia-thalamocortical circuits in a normal state (a) and in the untreated 
parkinsonian state (b). Red, green and yellow lines indicate glutamatergic, GABAergic and dopaminergic pathways, 
respectively. Increased activity in the average activity rate o f specific projection pathways are shown as thickening and 
decreased activity is shown as thinning of the corresponding lines compared with the normal state.
K ey: GPe, external segment o f the globus pallidus; GPi, intemalsegment o f the globus pallidus 
SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata;
STN, subthalamic nucleus.
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Therefore, patients with PD experience a disruption of the frontal-subcortical circuits 
due to a reduction of dopamine in the substantia nigra pars compacta (SNpc) resulting in 
alteration of the functioning of both the direct and indirect striatal pathways.
1.3 Treatment of PD
1.3.1 Drug Treatment
Levodopa is the most favoured drug for the treatment of PD symptoms. It acts to relieve 
the motor symptoms of PD as it is a metabolic precursor of dopamine and is therefore 
converted to dopamine, resulting in the normal functioning of the striatum and the 
reduction of symptoms (Crossman & Neary, 2000). However, there are disadvantages to 
treatment, as responsiveness to Levodopa lasts approximately five years, after which the 
effectiveness of the drug is significantly reduced (Limousin, 1998). Other disadvantages 
include side-effects of Levodopa treatment, including drug-induced dyskinesias 
(involuntary movements) and related motor fluctuations (Almedia & Hyson, 2008).
1.3.2 Surgical Treatment
Surgical treatments for PD include stereotaxic neurosurgical procedures involving Deep 
Brain Stimulation (DBS) of specific striatal areas, including the Subthalamic Nucleus 
(STN) and the Globus Pallidus interna (GPi), and the lesioning of specific areas, such as 
the GPi in Pallidotomy, or the STN in subthalamotomoy or the Thalamus in 
Thalamotomy (Speelman, 1991). The surgical treatment focused upon in this review is 
DBS of the STN, which aims to alter the pathological basal ganglia outflow with high 
frequency stimulation of the STN leading to an improvement of PD motor symptoms,
namely bradykinesia, tremor, rigidity and also improvement of dyskinesias (Limousin et 
al, 1995). Improvement in PD symptoms with STN DBS treatment have been reported at 
twelve months post-surgery, however benefits can also be sustained for several years 
(Rodriguez-Oroz et al, 2005). Liang et al (2006) in their long term follow-up study of 
patient’s with advanced PD who underwent bilateral STN DBS found that this surgery 
was an effective long term therapy.
DBS is an invasive surgical procedure involving the insertion of electrodes into the basal 
ganglia through the cranium. These electrodes are attached, via electrical leads which 
are placed beneath the skin of the scalp and neck, to a pace-maker like device called a 
neurostimulator, which is inserted beneath the skin of the chest of the patient. The 
neurostimulator may be activated and deactivated through the use of the separate control 
device, which when placed on the chest above the neurostimulator alters the electrical 
activity in the electrodes in the basal ganglia.
DBS is, therefore, a highly invasive surgical procedure. Patients are selected for surgery 
according to clinical criteria, namely diagnosis of PD, stage and severity of PD, as 
determined by Hoen and Yahr criteria and Unified Parkinson’s Disease Rating Scale. 
However, general health and ability to undergo a prolonged surgical procedure in a 
conscious state are also necessary to be eligible for DBS.
Although the procedure of STN DBS surgery is becoming increasingly refined and our 
understanding of the mechanism of how STN stimulation functions to ameliorate the 
motor symptoms of PD is still unclear. It has been hypothesised that stimulation acts as a
9
functional lesion, causing disruption of the pathological basal ganglia output to the
cortex.
STN DBS can improve all PD motor signs including to a lesser extent posture and 
balance problems (Pollack et al, 1998). PD motor symptoms are more improved by STN 
DBS than other surgical procedures, such as pallidotomy (Adam & Blanchette, 2004). 
However, although significant motor benefits of STN DBS have been reported, potential 
adverse effects of the surgery can be problematic. Adverse effects, namely non-motor 
outcomes including cognitive deterioration and behavioural disturbances can occur post- 
operatively in the short term, up to five years after surgery.
Figure 1(d). The location of electrodes and stimulator in deep brain stimulation of the 
subthalamic nucleus (Medtronic, 2006).
1.4 Non-motor outcomes of Subthalamic nucleus stimulation
Although STN DBS results in improvement of motor symptoms and quality of life of the 
patients, chronic stimulation has been found to have adverse effects on several areas of
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functioning, leading to cognitive deficits (Funkiewiez et al, 2004) and behavioural and 
psychiatric complications (Rodriguez-Oroz, et al 2005).
1.4.1 Cognition and executive function
Studies of the cognitive outcomes of STN DBS are mixed, however a number of deficits 
in cognitive functions are consistently apparent, namely verbal memory (Alegret et al, 
2001; Morrison et al, 2000; York et al, 2007), and visual memory (Saint-Cyr et al,
2000). Consistent deficits have also been found in phonemic verbal fluency (Alegret et 
al, 2001; Saint-Cyr et al, 2000), semantic verbal fluency (Alegret et al, 2001; Morrison 
et al, 2000; Saint-Cyr et al, 2000) and in visuospatial functioning (Alegret et al, 2001). 
Deficits have been found in executive functioning after STN DBS surgery, specifically 
in set-shifting, (Alegret et al, 2001; Morrison et al, 2000; Saint-Cyr et al, 2000), 
attention (Alegret et al, 2001), and in forming spatial and conditional associations 
(Alegret et al, 2001). However, with the exception of deficits in phonemic and semantic 
verbal fluency, which have been found to persist in long term follow up, the majority of 
the other cognitive deficits are short-lived and not observed in the long-term 
(Funkiewiez et al, 2006). Post-operatively, significant differences in specific aspects of 
cognition, namely verbal fluency, response selection under competition on the Stroop 
test and conditional associative learning have been reported with the stimulators on 
versus off (Jahanshahi et al, 2000; Pillon et al, 2000).
1.4.2 Mood
Reports of the affective outcome of STN DBS have been mixed, with some authors 
finding significant improvement in depression and anxiety after STN DBS (Krack et al,
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2001), and others reporting worsening of mood following surgery (Funkiewiez et al, 
2004; Stefurak et al, 2003). Compared to pre-surgical levels, self-reported depression 
and anxiety can be improved post-operatively (Castelli et al, 2006). This may simply 
reflect the reactive elevation of mood associated with improved motor function and the 
associated reduction of disability. In addition, a host of stimulation-induced behavioural 
and affective changes have been documented in reports. These have included actue 
depression and suicide (Funkiewiez et al, 2004; Stefurak et al, 2003), manic eposides 
(Funkiewiez et al, 2004), visual hallucinations (Krack et al, 2003), apathy (Funkiewiez 
et al, 2004; Krack et al, 2003), pseudobulbar crying (Okun et al, 2004), aggressive 
behaviour (Funkiewiez et al, 2004; Krack et al, 2003), and impaired processing of 
emotional facial expressions (Dujardin et al, 2004). While some of these affective 
responses may reflect amplification of pre-existing psychiatric problems (Houeto et al,
2002), others such as apathy, mania and aggressive behaviour have been mainly limited 
to the immediate post-surgical phase when stimulation has just been introduced and 
disappear over time (Krack et al, 2003).
In contrast, a number of studies have shown that stimulation of some electrode contacts 
result in acute alteration of affective state. Krack et al (2001) reported a patient whose 
depression and suicidal thoughts were alleviated with stimulation post surgery, however 
upon increasing stimulation this improved mood would culminate in fitful bursts of 
laughter that became problematic. They reported another patient whose mildly depressed 
mood and frustration was improved post-operatively; however upon chronic stimulation 
he became labile, laughing and crying more readily than normal with exposure to 
appropriate stimuli (Krack et al, 2001). This change persisted for the duration of
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stimulation. However, in a female patient, an increased depressive state with feelings of 
profound sadness, emptiness, fatigue, guilt and thoughts of death was found by Bejjani 
et al (1999), which persisted for the duration of stimulation. In a number of cases, 
adverse acute affective effects were observed when stimulating through contacts that 
were not in the STN (eg Bejjani et al, 1998). However, in most cases, behavioural 
effects are documented with electrodes accurately placed in the sensorimotor STN. It is 
apparent, therefore, that STN DBS can influence affective states in PD.
1.4.3 Social adjustment
In their study of patients with PD who underwent STN DBS surgery Schupbach et al 
(2005) found that although patients experienced motor improvement, showed no adverse 
effects on cognition, and reported improvement in quality of life and activities of daily 
living, social adjustment did not improve. This resulted in patients reporting difficulties 
in their relationships with their spouses and families and in their social interaction. 
Furthermore, a number of patients who were employed prior to surgery were unwilling 
to go back to work, despite improvement of their Parkinson’s disease and reduction of 
disability (Schupbach et al, 2005).
Therefore, due to the numerous potential non-motor outcomes of STN DBS surgery 
appropriate selection of patients is essential. This highlights the importance of 
neuropsychological assessment in the selection of suitable candidates for this surgery, as 
some patients, such as those with dementia, cannot benefit from surgery (Saint-Cyr & 
Trepanier, 2000).
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Therefore, it is apparent that as well as providing relief of motor symptoms through its 
actions on motor areas, DBS also affects non-motor functions, including affective, 
cognitive and psychosocial functioning. In the remainder of this review, the existing 
literature on apathy in PD and apathy in patients with PD who have undergone STN 
DBS will be discussed and critically appraised.
What factors influence the development o f apathy in PD?
1.5 Apathy in Parkinson’s disease
Apathy is a disorder that presents with behavioural, emotional and motivational features, 
including reduced interest and participation in purposeful behaviours, lack of initiative, 
affective flattening and indifference (Pluck & Brown, 2002), and is associated with a 
variety of negative outcomes (Roth, Flashman & McAllister, 2007). Marin’s (1991) 
definition of apathy is a primary loss of motivation in the absence of emotional distress, 
intellectual impairment or clouding of consciousness. The “negative symptoms” of 
apathy that can occur in various psychiatric and neurological disorders in the domains of 
cognition, emotion and behaviour, which can represent both a symptom and a syndrome 
signifying a loss of motivation, have been emphasised (Marin, 1991). Levy and 
Czemecki (2006) have defined apathy as the quantitative reduction of self-generated and 
purposeful behaviours that can, therefore, be understood as a pathology of goal-directed 
behaviour resulting from disruption of the basal ganglia and related circuits. They 
proposed the existence of three subtypes of apathy, namely apathy of cognition, emotion 
and auto-activation, each relating to a specific type of frontal-subcortical dysfunction, 
reflecting the disintegration of motivational, emotional and cognitive processes (Levy & 
Czemecki, 2006).
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Apathy in PD has been found to present as an isolated lack of motivation without 
anhedonia, hopelessness and low mood, which differs from the presentation of apathy in 
depression (Ferreri, Agboku & Gauthier, 2006). Rates of apathy in patients with PD 
vary, with some authors reporting rates between 12% (Starkstein et al, 1992) and 45% 
(Isella et al, 2002). This discrepancy may be due to reliance on divergent diagnostic 
criteria, assessment of different PD samples such as community versus hospital based 
samples or may reflect the lack of a validated, standardised instrument for detecting the 
presence and severity of apathy in this population (ibid). Some authors have suggested 
that apathy is a core feature of PD, as significantly higher levels of apathy have been 
found in PD patients than in matched controls with other neurological disorders, for 
example Dystonia (Kirsch-Darrow, Fernandez, Marsiske, Okun & Bowers, 2006). The 
factors influencing the development of apathy in Parkinson’s disease will be discussed 
below. Table 1 details these influencing factors.
1.5.1 Apathy and Dopamine
The deficiency of the neurotransmitter dopamine is the hallmark of PD (Brown & 
Jahanshahi, 1991). However, dopamine is also involved in reward and motivation 
(Dujardin et al, 2007). It has been proposed that dopamine deficiency underlies a 
number of disorders that cause apathy (Marin, 1991). Lack of motivation is an important 
element of apathy (Pluck & Brown, 2002), which some authors have stated is the 
cardinal feature of apathy in PD (Ferreri et al, 2006). However, Czemecki, Pillion, 
Houeto, Pochon, Levy and Dubois (2002) found that the severity of apathy in PD 
patients differed significantly between “on” and “o ff’ Levodopa states. They and other 
authors have suggested that apathy may be at least partially dopamine dependent and
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that dopaminergic medication may be helpful for the treatment of apathy (Czemecki et 
al, 2002; Roth et al, 2007), although this has been disputed by some authors (Brown & 
Pluck, 2000). Dopamine deficiency may, therefore, at least partly account for the high 
prevalence of apathy in PD.
1.5.2 Apathy and motor symptoms o f PD
Pluck & Brown (2002) in their comparative study of apathy in PD and equally disabled 
patients with osteoarthritis found that significant levels of apathy only occurred in the 
PD sample. On this basis they suggested that apathy is a true feature of PD and a direct 
consequence of the disease, rather than a psychological reaction to physical deterioration 
or adjustment to disability (Pluck & Brown, 2002). In accordance with this finding 
Dujardin et al, (2007) found no association between motor symptom severity and apathy 
in their study, implying that apathy is not a reaction to motor deterioration, but part and 
parcel of the disease process.
1.5.3 Apathy, the basal ganglia and frontal lobe dysfunction
In an analysis of the literature on basal ganglia lesions it was found that Abulia (apathy 
with loss of initiative, spontaneous thought and emotional responses) was the most 
common behavioural disorder arising from lesions in this area (Bhatia & Marsden, 
1994). Levy & Czemecki (2006) hypothesised that apathy occurring in PD may be the 
emotional subtype, due to dysfunction of the orbito-medial-PFC-ventral striatum circuit. 
This emphasises the role of the frontal-subcortical circuits in both apathy and PD. 
However, they also offer an alternative hypothesis for the occurrence of apathy in PD, as
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presenting as the cognitive subtype, resulting from disruption in cognitive executive 
processing leading to deficits in planning and organization of goal-directed behaviours.
Apathy has been related to frontal lobe dysfunction as it often occurs following damage 
to the frontal lobes or related structures, such as the basal ganglia (Dujardin et al, 2007). 
As apathy is commonly seen in patients with basal ganglia disorders the involvement of 
the frontal-subcortical circuits have been suggested in the development of apathy. Clear 
associations between apathy and executive dysfunction have been reported by many 
authors including Pluck & Brown (2002), Isella et al (2002) and Starkstein et al (1992), 
who found that apathetic PD patients perform worse on tests of executive function such 
as the Controlled Oral Word Association test and Trail making test B. On tasks of 
executive function PD patients have been found to perform worse than healthy controls 
(Pluck & Brown, 2002). This supports the hypothesis that the frontal-subcortical circuits 
are involved in both apathy and PD.
1.5.4 Apathy and Depression
Although apathy and depression often co-exist in PD, some authors have found that 
despite this correlation, the presence of one disorder did not predict the presence of the 
other (Pluck & Brown, 2002; Sockeel et al, 2006). However, it has been found that, if 
present, the severity of depressive symptoms contributes to the overall severity of apathy 
(Dujardin, 2007). Isella et al (2002) found no correlation between apathy and depression 
in their sample of thirty PD patients, 33% of whom were apathetic in the absence of 
depression and 44.4% were depressed in the absence of apathy.
17
Levy et al (1998), in their study, of 154 patients with neurological disorders also found 
no correlation between apathy and depression. However, this study did not focus 
specifically on PD, and they found that few PD patients presented with apathy alone (n = 
2; 5%), compared with depression (n = 11; 28%) or depression plus apathy (n = 11; 
28%). The importance of increasing our understanding of apathy in PD and 
distinguishing depression and apathy in this group has been highlighted (Kirsch-Darrow 
et al, 2006). This is especially important when considering the negative outcomes with 
which apathy is associated and the potential necessity for treatment with both 
pharmacologic and psychological treatments (Roth et al, 2007).
1.5.5Apathy and Cognitive impairment/ Dementia
Dementia occurs in approximately 30% of patients with PD (Anderson, 2004) and has 
been positively correlated with the presence of apathy in PD, (Brown & Pluck, 2000). 
Dujardin et al (2007) found that apathy profiles vary according to the clinical 
presentation of PD, finding relatively few cognitively stable patients and a modest 
number of patients with cognitive fluctuation were apathetic. They found, however, that 
PD patients with dementia were more likely to suffer apathy and that cognitive 
impairment was the main factor contributing to the worsening of apathy (Dujardin et al, 
2007). This, therefore, suggests an association between cognitive impairment and apathy 
in PD. Levy et al (1998) also found an association between apathy and cognitive 
impairment in PD and Alzheimer’s disease populations.
Pluck and Brown (2002) found that, although patients with dementia made up only a 
small proportion of their sample, all of them were defined as apathetic. They suggested,
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on this basis, these patients may be in the extreme range of dysfunction or may represent 
a subgroup of PD patients, with marked apathy and cognitive dysfunction, which are the 
hallmarks of classic fronto-subcortical dementia. However, in contrast, other authors 
including Isella et al (2002) and Starkstein et al (1998) found no relationship between 
performance on global cognitive tests or specific memory tests and apathy and therefore 
concluded that there is no relationship between apathy and cognitive impairment in PD.
1.5.6 Apathy and other psychiatric sequalae in PD
Drugs used to treat PD, such as levodopa, can have adverse neuropsychiatric effects, 
most prominently psychosis and delirium (Young, Camicioli & Ganzini, 1997). 
Santangelo et al (2007) found that patients who experienced hallucinations had higher 
apathy scores than those who had not experienced hallucinations. However, the nature of 
apathy and the behavioural manifestation of the disorder seem at odds with some other 
psychiatric disorders, such as the hypervigilence of anxiety (Pluck & Brown, 2002).
Table 1(a). Factors associated with the occurrence o f apathy in PD
Study Cognitive
impairment
Depression Executive
dysfunction
Other 
psychiatric 
se quale
Motor
symptoms
Dementia
Pluck & Brown (2002) d X d X X d
Dujrdin et al (2007) d X d
Funkewiez et al (2006) d
Santangelo et al (2007) d
Levy et al (1998) X d
Isella et al (2002) X X d X
Starkstein et al (1998) X d X
Legend:
x  = Not associated with the occurrence o f apathy in PD. 
d = Associated with the occurrence o f apathy in PD.
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Table 1(a) illustrates some of the main findings of the aforementioned studies. It is 
apparent that although the factors influencing the occurrence of apathy in PD are 
controversial, there are a number of potential risk factors which increase the likelihood 
of apathy in this population. The main risk factors are the presence of dementia and 
executive dysfunction. The presence of depression, severity of motor symptoms and 
other psychiatric sequalae have been found to not influence the occurrence of apathy in 
PD. However, conflicting results have been found regarding the influence of cognitive 
impairment on apathy in PD. This may be due to differing inclusion criteria, differing 
definitions of impairment and incongruent samples used in different studies.
What influence, if  any, does STN DBS have on apathy?
1.6 Apathy and STN DBS surgery
The question of whether DBS of the STN in Parkinson’s disease influences apathy is a 
controversial one, and has wide ranging implications for treatment of patients with PD. 
The investigation of apathy after STN DBS surgery is important as although patients 
may obtain great motor benefit from surgery, if there is a risk of increased or newly 
induced apathy, this could have significant implications; initially for the selection of 
candidates for surgical treatment and subsequently for patients quality of life and carer 
burden. If apathy is found to be a common occurrence following DBS of the STN, this 
may influence the patients and families decisions about whether or not to have surgery.
1.6.1 Occurrence o f apathy after STN DBS
Some authors have concluded that STN stimulation may induce apathy or that apathy 
may worsen after such surgery. Studies have shown that apathy worsens in comparison
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to preoperative assessment after STN DBS surgery at three months and six months 
postoperatively in the absence of depression or worsening of existing anxiety levels 
(Drapier et al, 2005). Saint-Cyr et al (2000) also found increased reports of apathy as 
assessed by carer responses on the Frontal Lobe Personality Scale by carers at 9 -  12 
months post-surgery, suggesting worsening of apathy. A study comparing the 
neuropsychological outcomes of PD patients who underwent either pallidotomy 
(lesioning of the GPi) or STN DBS found that post-operative frontal lobe behavioural 
changes occurred in both groups (Trepanier et al, 2000).
Temel et al (2006) in their systematic review of behavioural changes after bilateral STN 
stimulation in advanced PD found that apathy was reported in <0.5% (n = 7) of the 1398 
patients included in their selected studies. They did however note that although rates of 
apathy were low, when it occurred apathy was often chronic and had substantial effects 
on the patients and their families (Temel et al, 2006). A three-year long term follow-up 
study of seventy-seven patients also found newly occurring cases of apathy and 
worsening of pre-existing apathy, with overall group rates rising from 8.7% pre- 
operatively to 24.6% post-operatively (Funkiewiez et al, 2004).
Although it has been reported that acute effects of stimulation initially result in 
improvement in motivation, apathy has been found to worsen after chronic stimulation 
(3 months post surgery) in the same patient group (Funkiewiez et al 2006). In this study 
of twenty-two patients, new cases of apathy were found in four patients, and an existing 
pre-operative case of apathy persisted after surgery (Funkiewiez et al, 2006). Not all of 
the new cases in this study were above cut-off point for diagnosis of clinical apathy;
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however the occurrence of apathy in these patients was sufficiently significant to be 
reported as problematic by patients and families, thus highlighting the difficulty 
encountered by patients experiencing apathy and the carer burden resulting from it.
Schupbach et al (2005), in their 5-year follow-up study of STN DBS found newly 
occurring cases of apathy, half of whom were transient (n = 4) and the other half 
permanent (n = 4). The authors noted that the apathetic patients’ activities of daily living 
(ADL) had returned to baseline pre-operative levels at 24 months after surgery. They 
concluded that this reduction in ADL may have occurred due to the adverse effects of 
apathy (Schupbach et al, 2005).
1.6.2 Improvement/ no change in apathy after STN DBS
Castelli et al (2006) found apathy to be stable preoperatively and 15 months after STN 
DBS surgery. Contarino et al (2006), in their 5-year follow-up study of STN DBS in 
PD, found that one of the eleven patients studied developed apathy. The authors 
concluded that the surgery had a low cognitive and behavioural morbidity rate and was, 
a safe procedure, however, this study did not include a non-operated control group for 
comparison of neuropsychological and behavioural outcome of surgery. Other 
investigators have found that STN stimulation can in fact improve apathy (Czemecki, et 
al, 2006). This study has been criticised, however, as the results were obtained by 
comparison of presence of apathy under “on-stimulation” versus “off stimulation” 
conditions, which is not an appropriate assessment procedure for apathy, as it is unlikely 
to be state dependent. It should also be noted that in their sample of 23 patients, the
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authors reported improvement in apathy in nine patients, no significant change in eight 
patients and aggravation of apathy in one patient (Czemicki et al, 2005).
1.6.3 Differences amons those who develop apathy vost-on and those who do not 
Czemicki et al (2005) highlighted the importance of appropriate pre-operative patient 
selection, according to specific criteria, as they found that younger patients with 
moderate disease duration and severity did not develop apathy post-operatively. Other 
authors, have suggested that older patients may be more likely to develop adverse effects 
from STN DBS surgery, such as apathy and difficulties in executive functioning, as their 
neural networks may not be as flexible as younger patients (Jahanshahi, et al 2000). 
Apathy and age at surgery were found to be correlated, in the absence of a relationship 
between cognitive outcome and age in a study of the influence of aging on outcome in 
STN DBS surgery at two-year post-operative follow up (Ory-Magne et al, 2007). A 
correlation was also found between depression and aging in this study; where older 
patients were more likely to become apathetic or depressed post-operatively (Ory- 
Magne et al, 2007).
1.7 Apathy, Parkinson’s disease and the Frontal-subcortical circuits
As aforementioned, Alexander et al (1986) identified the five frontal-subcortical circuits, 
connecting the frontal lobes and striatum, limbic and thalamic structures. Among the 
circuits they identified was the Anterior Cingulate Circuit (ACC), which Cummings 
(1993) suggested was involved in apathy. This circuit was found to be important in 
motivational mechanisms (Bonelli & Cummings, 2007). Apathy is a prominent feature 
of disorders associated with lesions to this circuit, e.g. akinetic mutism and abulia.
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Evidence from animal studies highlights the role of dopamine in this circuit as, 
behavioural deficits occurring as a result of an induced state of akinetic mutism could be 
reversed by administration of dopamine agonists (ibid). Dujardin et al (2007) suggested 
that the high prevalence of apathy in PD confirms the involvement of the frontal- 
subcortical circuits.
Evidence from clinical-pathology and functional neuroimaging suggests that the frontal- 
subcortical pathways mediate executive dysfunction and apathy in degenerative 
neurological disorders, including PD (Kuzis, Sabe, & Tiberti, 1999). Therefore, the 
disruption of the frontal-subcortical connections, may underlie the pathogenesis or co­
occurrence of apathy, executive dysfunction and Parkinsonian signs (Alexander & 
Crutcher, 1990).
1.8 Outcome of apathy in PD
It is apparent, therefore, that a number of factors influence the development of apathy in 
patients with PD. Some of these factors are controversial, as contradictory evidence 
exists for their involvement in or association with apathy in PD. There are many reasons 
for this contradictory evidence, including different methods of data collection, namely 
tools for identifying and diagnosing apathy and differing age groups and prior 
psychiatric profiles of the patients included. With reference to apathy in patients who 
have undergone STN DBS surgery for the amelioration of their PD symptoms, it must be 
acknowledged that surgery of this kind is still in relative infancy, and more research 
must be done to assess its long-term effects.
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Despite this, the fact remains that apathy is prevalent in PD, both in patients who receive 
pharmacological treatment and patients who receive surgical treatment with DBS of the 
STN. Therefore the clinical and real life implications of apathy must be considered. It 
has been reported by many authors that when apathy occurs in patients with PD it is 
consistently reported by patients and caregivers as a concern, even if the apathy is below 
clinical levels of significance. This may be due to the negative influence of apathy on 
quality of life and activities of daily living (Pluck & Brown, 2002).
1.9 Treatment of Apathy in patients with Parkinson’s disease
1.9.1 Pharmacological and surgical treatment
It has been reported that apathy appears to respond to dopamine agonists (Roth et al, 
2007). However, apathy in patients with PD may also respond to cholinesterase 
inhibitors (Lauterbach, 2005), which have been found to reduce apathy in patients with 
dementia and traumatic brain injury (Roth et al, 2007). However, clinical benefits of 
pharmacological treatment of apathy in PD, including dopamine agonists or 
methylphenidate are reported to be disappointing and limited by side-effects (Ferreri, et 
al, 2006). Some authors have found acute improvement in apathy after STN DBS 
(Czemecki et al, 2005), however the long term implications of surgical intervention and 
long term high frequency stimulation on apathy need further assessment as the evidence 
is contradictory.
1.9.2 Psychological Intervention
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Ferreri et al (2006) have found that “psycho-education” of patients and caregivers helps 
them to distinguish apathy symptoms from depression and laziness. They recommend 
coaching and prompting to help decrease the difficulties of executive dysfunction and 
planning, and greater control of Parkinson’s symptoms to help alleviate apathy (Ferreri 
et al, 2006). Further study is required to determine the efficacy of additional 
psychological approaches for patients with PD who experience apathy.
1.10 Conclusions
The factors influencing the occurrence and development of apathy in PD are 
controversial, however, it appears that damage to the basal ganglia or frontal lobes, 
psychiatric phenomena, namely hallucinations and dementia are risk factors for apathy 
in patients with PD, as it appears that higher rates of apathy occur in PD patients who 
experience these difficulties. Factors that do not appear to influence apathy in this 
patient group are motor symptom severity and presence of depression. However, 
although depression does not predict the occurrence of apathy in PD, the presence of 
depressive symptoms increases the severity of apathy.
Dopamine deficiency may potentially account for the prevalence of apathy in PD, as 
apathy in PD appears to be at least in part dopamine-dependant, (Czemecki et al, 2008; 
Czemecki et al, 2002). However, non-dopaminergic circuits have also been implicated 
in the development of apathy in PD, as a link has been found between apathy and 
cognitive impairment in patients with PD (Dujardin et al 2007; Pluck & Brown, 2002).
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The influence of STN DBS and other surgical interventions for the treatment of PD on 
apathy is unclear, with studies finding conflicting results. Therefore further investigation 
of apathy in post-operative patients is required. However, despite conflicting findings, it 
appears that certain risk factors may exist that mean specific PD patients are at higher 
risk of developing apathy post-operatively. These risk factors are increased age, longer 
pre-operative disease duration, and a higher UPDRS score, indicating worse motor 
symptom severity.
STN DBS in PD is a relatively new surgical procedure, having been developed initially 
only twenty years ago (Benabid, 2007). It is impossible, at this stage, to determine the 
longer-term effects of this surgery, however due to the negative effects of apathy for 
both patients and caregivers the need for continued study of apathy in post-operative 
patients is highlighted. This is important so as to identify the potential risks of apathy 
after surgery and potential prognostic indicators for this, which the patients would need 
to weigh against the great motor benefit that they could experience.
1.11 Clinical implications and future directions
1.11.1 STN DBS Patient selection
These findings highlight the need for thorough neuropsychological assessment of both 
the cognitive and affective domains in all patients with PD who are candidates for STN 
DBS surgery. However, as some studies have found that apathy can occur in patients 
with no prior history of the disorder the importance of informing patients and families of 
risk of developing apathy after surgery is also highlighted. This would allow them to 
make informed decisions regarding undertaking surgery for the alleviation of motor
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symptoms, which may result in affective side effects known to cause distress and 
negative outcomes for both patients and families. In the light of the findings of the 
aforementioned studies these risk and benefits must be weighed up with respect to 
candidate selection by clinicians on one hand and informed consent of patients 
considered for surgery on the other.
1.11.2 Role o f psychology in the assessment and treatment o f apathy in PD 
Therefore, it is apparent that numerous factors may influence the development of apathy 
in patients with PD. The prevalence of apathy in PD is high and the consequences of 
apathy in this group are negative for both the patient and their caregivers. At the clinical 
level, psychology services, therefore, have an important role to play in the assessment 
and treatment of patients with PD who develop apathy and in the support of their 
families and caregivers. On a research level, psychologists must also continue to study 
apathy in PD and evaluate the interventions that can be provided to reduce its negative 
effects on patients and their broader life contexts.
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Part 2. Empirical Paper
“The impact of Deep Brain Stimulation of the Subthalamic 
nucleus on reward responsiveness in patients with Parkinson’s
disease”
Abstract
Parkinson’s disease (PD) results from the degeneration of dopamine-producing cells in 
the striatum, leading to excessive inhibition of frontal areas and the motor symptoms of 
PD. Deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) is an effective 
treatment for PD motor symptoms. This study aimed to investigate the effect of STN 
DBS on reward responsiveness, assessed by performance on a ‘reaction time and 
reward’ paradigm and a card-sorting task in both “on” and “o ff’ stimulation conditions. 
Matched healthy controls performed the reaction time paradigm and card-sorting task 
twice. Hypothesis one proposed that STN DBS would speed up initiation and movement 
times for patients in the “on” stimulation condition as compared with the “o ff’ 
stimulation condition. This was supported of movement time, and a trend towards 
significance was found for improvement in initiation time. Hypothesis two proposed that 
the presence of reward would speed up initiation times in patients and controls. This 
was supported. Hypothesis three proposed that STN DBS would improve patients 
initiation time in response to reward conditions to a greater extent than repetition would 
improve controls initiation time. This was not supported. Hypothesis four proposed that 
STN DBS would improve patients performance on the CARROT card sorting task in 
response to reward conditions to a greater extent than repetition would improve controls 
performance on this task. This was not supported. Hypothesis five stated that the 
presence of a warning signal would improve patients initiation time, this was supported. 
Hypothesis five proposed that the presence of a warning signal would significantly 
improve patients initiation time. This was supported. The results are discussed with 
reference to the effects of STN DBS on response time, reward responsiveness and the 
proposed neural circuits mediating motivation and the limitations of the current study.
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Introduction
2.0 Parkinson’s disease
Parkinson’s disease (PD) is a movement disorder arising from the death of striatal 
dopaminergic neurons and subsequent deficiency of dopamine, resulting in the excessive 
inhibition of cortical motor areas, which leads to the characteristic symptoms of 
bradykinesia (slowness of movement) and akinesia (poverty of movement) (Crossman & 
Neary, 2000). In PD the balance of activity in the frontal-subcortical pathways are 
affected (Alexander De Long & Strick, 1986).
The level of deficiency in PD appears to be at the translation of intention into action, as 
patients with PD know what they want to do but cannot translate this into activity (Frith, 
1992). This hypothesis is supported by the phenomenon of “kinesia paradoxica”, or 
paradoxical kinesis, where PD patients have been known to move suddenly and quickly 
in response to urgent external stimuli, eg: in response to a dangerous situation (Ballanger 
et al, 2006; Niv & Rivlin-Etzion, 2007). The fact that external cues can help PD patients 
improve their performance on experimental movement tasks, such as preventing a ball 
dropping by pressing a switch (Ballanger et al, 2006) and in real world situations, such 
as the provision of lines on the floor where a patient is required to walk (Jahanshahi & 
Frith, 1998) also supports this hypothesis. Therefore, PD could be considered a disorder 
of willed action.
2.0.1 Reaction time studies
One way of experimentally assessing movement deficits in PD is through reaction time 
studies, which usually take the form of manual tasks requiring the patient to move as
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quickly as possible from one response button to another. Two reaction times are 
differentiated in this paradigm, namely initiation time, which is estimated as the time it 
takes for the participant to lift his/her finger from the response key upon presentation of 
the imperative stimulus and movement time, which is estimated as the time it takes 
between the participant lifting his/her finger from the response key and pressing the 
target key upon presentation of the imperative stimulus.
Reaction time studies can tell us more about PD symptoms as they allow the 
differentiation between cognitive and motor impairments of the disease (Kutukcu, 
Marks, Goodwin & Aminoff, 1999). Reaction time paradigms enable this dissociation as 
initiation time, which is associated with cognition, namely motor planning and 
motivational processes, and movement time, which is associated with motor function, 
can be assessed individually on these tasks (Temel et al, 2006). Therefore, reaction time 
studies in PD can yield valuable information about the symptoms of the disease and the 
neural systems that underlie these deficits.
Simple reaction time (SRT) studies, where participants make the same response to the 
same stimulus over trials have found that reaction times are impaired in patients with PD 
compared with healthy controls (de Frias, Dixon, Fisher & Camicioli, 2007; Kutukcu et 
al, 1999; Mazzucchi et al, 1993), and show a greater intraindividual variability of 
response than healthy controls (de Frias et al, 2007; Erbmeier et al, 1992). Patients with 
PD have deficits in both initiation times (Evarts, Teravainen & Caine, 1981) and 
movement time (Erbmeier et al, 1992) relative to age-matched controls.
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Advanced warning cues are sometimes used in reaction time studies to investigate the 
effects of warning on initiation and movement time. These warning cues precede the 
imperative stimulus and therefore warn the participant of the imminent occurrence of the 
stimulus. Studies looking at the effects of warning cues on reaction time in PD suggest 
that PD patients benefit from advance warning signal in speeding reaction time 
(Jahanshahi, Brown & Marsden, 1992). Jahanshahi, Brown and Marsden (1993) found 
that PD patients are more dependent on warning to improve their performance on SRT 
tasks in comparison to patients with Huntington’s disease or cerebellar disease, and 
concluded that PD patients selectively require this external stimulus to maintain motor 
readiness.
2.1 Reaction time in patients with PD who have undergone STN DBS surgery
The Subthalamic Nucleus (STN) is a subcortical structure, with both somatomotor, 
limbic and cognitive functions, which forms part of the basal ganglia (Crosman & 
Neary, 2000). In PD there is excessive excitatory drive from the STN (Alexander et al, 
1986). As dopamine replacement drug therapy has time-limited effects; giving relief of 
symptoms for approximately five years, after which hard-to-control motor fluctuations 
develop, STN Deep brain stimulation (DBS) is a neurosurgical treatment option for the 
reduction of symptoms of PD using high frequency stimulation (HFS) of the STN 
(Limousin, et al 1998). It has been proposed that the improvement of motor symptoms 
results from the direct inhibition of STN over-activity and by influencing the motor 
frontal-subcortical circuit (Czemecki et al 2005), which is one of a group of five 
parallel, segregated functional circuits that link specific areas of the basal ganglia with 
discrete areas of the frontal cortex (Bonnelli & Cummings, 2007; Cummings, 1993). The
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motor, cognitive, affective and motivational functions of the striatum are mediated 
though the direct and indirect pathways of these circuits (Alexander et al, 1986).
Reaction time studies of patients who have undergone STN DBS can further inform us 
about the functions of the STN in PD and its influence on both the motor circuitry and 
the other frontal-subcortical circuits involved in affect and motivation (Alexander et al, 
1986). Evidence suggests that STN DBS affects the Anterior Cingulate Circuit (ACC), 
which mediates motivated behaviour (Czemecki et al, 2005). Studies have found that 
initiation and movement times in patients who have undergone DBS for the treatment of 
PD are significantly improved in the “on” stimulation state (Ellrichmann, Harati and 
Muller, 2008; Kumru et al 2004), however response times within this group remain 
slower than healthy controls (Temel et al 2006).
However, one area which to date has received little attention in PD and healthy 
populations is motivational influence on initiation and movement speed. Healthy people 
can improve the speed of motor performance when motivated for example writing faster 
during an exam or walking faster when in a hurry to avoid being late. Therefore, 
motivation can influence motor speed.
2.1.1 The Role o f Dopamine in Reaction time deficits in PD
Gauntlett-Gilbert & Brown (1998) suggest that dopamine deficiency is a factor 
underlying reaction time deficits seen in PD, as these deficits are rectified by the 
administration of dopamine replacement therapy, where slower reaction times, which 
require less dopamine recover before faster reaction times. Lalonde and Botez-Marquard
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(1997) found that both simple and choice reaction times are susceptible to modulation by 
brain dopamine levels; however they also raise the issue that other non-dopaminergic 
neurons contribute to sensorimotor slowing in PD (Lalonde & Botez-Marquard, 1997). 
However, Jahanshahi et al (1992) found that reaction times in PD were not dopamine 
dependent, suggesting that RT slowness may be a non-specific index of brain 
dysfunction present in other disorders such as Huntington’s disease, cerebellar disease 
(Jahanshahi et al, 1993) or dystonia (Jahanshahi et al, 2001) rather than representing 
dopamine deficiency.
2.2 Dopamine, Reward and Motivation
2.2.1 Dopamine and Reward
Reward, which can be monetary or some other desired object, acts as a positive 
reinforcer in goal directed behaviour, as objects signalling reward are labelled with 
positive motivational value, which increases the likelihood of engaging in specific 
behaviours that will lead to obtaining that reward (Martin-Soelach et al, 2001). Studies 
of reward related behaviour suggest that the striatum and related areas of the brain are 
involved in the processing of reward related information (Nieoullon & Coquerel, 2003).
Dopamine depletion is accepted as the causal process in Parkinson’s disease. In addition 
to motor control, dopamine neurotransmission also has other functions in the brain; it 
has effects on motivation, reward-related information processing and behaviour 
(Berridge & Robinson 2003; Tricomi et al 2004) and has been implicated in the 
detection of novelty (Nieoullon & Coquerel, 2003). Arias-Carrion and Poppel (2007)
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state that reward anticipation or omission results in changes in the activity of 
dopaminergic neurons, suggesting a role for this neurotransmitter in motivation
Disorders of motivation, specifically apathy, are reported to occur in PD (Isella et al,
2002). Rates of apathy in patients with PD vary, with some authors reporting rates 
between 16 and 42% (Sockeel et al, 2006). Lack of motivation is an important element 
of apathy (Pluck & Brown, 2002), which some authors have stated is the cardinal feature 
of apathy in PD and differentiates it from the presentation of apathy in depression 
(Ferreri, Agboku & Gauther, 2006). Therefore, not only does dopamine have motor 
functions within the brain, but it also influences motivation.
2.2.2 The modulation o f reaction times by monetary incentive
Czemecki et al (2002), in their study of motivation and reward in PD found patients 
treated with dopaminergic medication in the “o ff’ medication condition had lower 
motivation and had impaired sensitivity-to-reward flexibility. In the “on” medication 
state they found PD patients had improved motivation (Czemecki et al, 2002). From 
these findings the authors concluded that the limbic frontal-subcortical circuits, which 
are dysfunctional in PD, were implicated in motivation.
Reward responsiveness refers to the modulation of a specific behaviour by the presence 
of a reward. In a study comparing effects of basal ganglia damage on reward 
responsiveness Schmidt et al (2008) found that, in response to in monetary incentive, PD 
patients “o ff5 dopaminergic medication were able to modulate their grip-force in 
response to reward, although at a lower rate than controls. The authors suggested that
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such functional preservation may occur due to spared dopaminergic innervation of the 
limbic circuits passing from orbital and medial prefrontal cortices through the basal 
ganglia (ibid).
The study of Mir et al (In press) focused on the effect of monetary reward on reaction 
times of healthy participants. They found that monetary incentive significantly speeded 
up initiation time in reaction time tasks. Therefore it appears that monetary reward was 
an incentive to speed up initiation of movement in these tasks. As initiation time was 
more significantly affected than movement time the authors concluded that the main 
effect of monetary incentive was on the pre-movement processes rather than on the 
execution of the movement (Mir et al, In press).
2.3 Summary
Parkinson’s disease represents a disorder characterized by dopamine deficiency, which 
can be considered to be a disorder of willed action, manifested by slowed movements 
and a reduction in spontaneous movement. Reaction time studies have found that PD 
patients have slower simple reaction times than controls. However, external cues can 
help patients with PD to improve motor performance. Studies using financial reward 
have found that reward can act as an incentive for healthy participants to improve 
reaction times. Dopamine is a neurotransmitter with both motor and motivational 
consequences and is deficient in PD. Treatments for PD include dopaminergic 
medication and neurosurgical techniques, including STN DBS, which it has been 
suggested, alleviates PD symptoms by operating as a functional lesion. Schmidt et al 
(2008) found that patients with basal ganglia lesions fail to distinguish between
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monetary incentives. Therefore, in light of the dopamine deficiency in PD and the 
mechanism of STN DBS treatment, it is of interest whether patients are capable of 
speeding up their reaction times in anticipation of monetary reward in a similar manner 
to healthy controls.
2.4 Aim
The aim of this study was to investigate the effect of DBS of the STN on processes of 
response initiation and execution, and reward responsiveness in patients with PD in 
unrewarded conditions compared to two rewarded conditions where patients were 
instructed to speed up their reaction times in anticipation of incremental monetary 
incentive, on a computerised task and on a manual card-sorting task. The performance of 
the patients with DBS “on” versus “o ff’ was compared to matched controls who 
performed the same tasks and conditions twice, to control for practice effects.
Based on the existing evidence in relation to STN DBS, reaction times and reward, the 
following hypotheses were formulated:
(1) STN DBS would speed up initiation time and movement time for patients in the 
“on” stimulation condition as compared with the “o ff’ stimulation condition.
(2) The presence of reward would speed up initiation time in patients and controls.
(3) STN DBS would improve patients initiation time in response to reward 
conditions to a greater extent than repetition would improve controls initiation 
time in response to reward
(4) STN DBS would improve patients performance on the CARROT card-sorting 
task in response to reward conditions to a greater extent than repetition would 
improve controls performance on this task in response to reward.
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(5) The presence of a warning signal would improve patients initiation time.
Method
In order to test these hypotheses, 12 patients with Parkinson’s disease (PD) who had 
undergone Deep Brain Stimulation (DBS) surgery of the Subthalamic Nucleus (STN) for 
the treatment of their motor symptoms and 11 age-matched controls were assessed on a 
computerised reaction time task and a card sorting task in order to determine reward 
responsiveness. A range of cognitive, mood and personality measures were also used to 
compare the relationship of reward responsiveness in DBS patients and controls on these 
variables.
2.5 Research design
A mixed between groups (PD patients vs controls) and within subjects design (DBS on 
vs off for the patients or time 1 vs time 2 assessment for controls) was used.
2. 6 Power Analysis
The following power calculation was used to determine the sample size necessary to 
obtain sufficient power significant effects; [sd2/ (|i2-|iil)2 x 10.5]. On the basis of this 
calculation a sample size of 16 was determined to be necessary. On the basis of time 
limitations, patient availability and inclusion criteria 12 patients were included in the 
study and 10 successfully completed the protocol. Therefore the current study is 
underpowered. However, as the population is extremely small and the protocol for this 
study necessitated a long period off stimulation and medication, the prospect of finding
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difficulty obtaining a sample size of 16 was considered. Therefore, sample sizes from 
published articles on DBS using similar protocols were also investigated and it was 
found that other authors used similarly small sample sizes; namely Mir et al (in press) (n 
= 16); Mazzoni et al (2007) (n = 7); and Ballanger et al (2006) (n = 6). Therefore, 
although this study is underpowered and this is an obvious limitation for the 
interpretation of results, the sample obtained was considered sufficient in the context of 
the population and time limitations for the purposes of this research.
2.7 Participants
2.7.7 Patients
The PD patients were all current patients at the National Hospital for Neurology and 
Neurosurgery in Queen Square, London, who had undergone DBS surgery in the 
Functional Neurosurgery Unit performed by the same surgical team, (M. Hariz, K. 
Ashkan, L. Zrinizo). The patients were identified from existing clinical lists and 
potential candidates were recommended by the Consultant Neuropsychologist (M. 
Jahanshahi) and post-doctoral research fellow (L. Wilkinson), both specialising in the 
study and clinical assessment of movement disorders.
Patients were selected on the basis of having undergone bilateral STN DBS surgery at 
least six months prior to entering the study. Patients with known psychiatric history or 
cognitive impairment were excluded. Only surgical patients with a good response to 
DBS, substantial improvement of clinical symptoms and post-surgery MRI evidence of 
correct positioning of the electrodes were included. Patients were also selected on the 
basis of being willing to remain off stimulation for approximately forty-five minutes,
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while also off medication. Thirteen PD patients were identified as potential participants 
and approached to participate in the study; one patient refused due to extreme motor 
difficulty experienced when off stimulation. Twelve patients agreed to participate; two 
patients were unable to successfully complete the study due to extreme motor difficulty 
during the off stimulation state, namely dystonic cramps and pain. Therefore, 10 patients 
successfully completed the study. Patients were tested off dopaminergic medication, 
after overnight withdrawal of medication for an average of 15 hours (SD = 3 hours, 
range 11 to 20 hours). Demographic and clinical characteristics of the patients are 
presented below in Table 2 (a).
Table 2(a). Demographic and clinical characteristics o f the patients with Parkinson’s
disease
Neurological characteristics Mean (SD) Range
Age at onset (years) 43(7) 3 9 -7 8
Duration o f disease(years) 14(5) 8 - 2 4
UPDRS “o f f ’ stimulation score 42(16) 2 2 - 7 6
UPDRS “on ” stimulation score 22(7) 1 1 - 3 6
Hours off medication 15(3) 1 1 - 2 0
UPDRS -  Unified Parkinson’s Disease Rating Scale o f motor symptom severity
2.7.2 Controls
Healthy controls were recruited from the list of healthy participants lists maintained by 
the Cognitive Motor Neuroscience Group of the Sobell Department of Motor 
Neuroscience and Movement Disorders and also through local advertising. They were 
selected on the basis of good general health, and none had any history of neurological or 
psychiatric illness, head injury or drug or alcohol misuse. Fifteen potential controls were 
identified and approached to participate in the study and four refused. Therefore, eleven
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healthy controls were included in the study. Demographic characteristics of the two 
groups are shown in Table 2(b).
Table 2(b). Demographic characteristics o f PD patients and controls.
Group Mean Age 
(SD)
Mean
Education
(SD)
Mean IQ 
(SD)
Mean
MMSE
(SD)
Handedness
Right:Left
PD patients 58(11) 14 (3) 110(13) 29 (2) 6:4
Controls 57 (15) 15(3) 128 (4) 29(1) 10:1
2.7 Procedure
Ethical approval was given for this study by the Joint Ethics Committee of the Institute 
of Neurology and the National Hospital for Neurology and Neurosurgery. Patient and 
(Ethical approval can be found in Appendix A). All participants gave informed consent 
and were assessed in a laboratory using the same procedure by the same investigator 
(AH). (Patient and Control Consent forms can be found in Appendix B).
To assess the effect of reward on motor performance two different tasks were used; 
namely the computer-based Simple Reaction Time (SRT) test and the Card Arranging 
Reward Responsitivity Objective Test (CARROT) card sorting test. The DBS patients 
underwent these tests twice, once with stimulators off and once with stimulators on. The 
healthy controls also completed the tests twice, so as to control for practice and fatigue 
effects. All participants also completed a number of additional measures of cognition, 
mood and personality.
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2.7.1 Experimental Tasks
2.7.1.1 Simple Reaction time (SRT)
Equipment
The SRT task entailed the participant making responses on a purpose-made response 
box, in reaction to a stimulus presented on a computer screen. Responses were made on 
a box with two buttons, a home key and a response key, illustrated in Figure2(a). The 
buttons were 2.54 cm in diameter and placed in a vertical row. The buttons were spaced 
10.16 cm vertically. This response box was linked to a computer with a 14-inch monitor 
on which the stimuli were displayed. Demonstration and practice trials were provided 
before beginning the task.
Computer connection
O
O
- Home key
- Response key
Figure 2(a) The response box with home and response keys.
Warned and unwarned Simple Reaction time
The participants sat in front of the computer monitor and were instructed to hold down 
the home key with the index finger of their right hand. A fixation cross was presented on 
the screen and, at intervals; a solid white box (response stimulus) was superimposed on
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the fixation cross. The presentation of this stimulus required the participant to respond 
by lifting their right index finger from the home key and moving to the response key as 
quickly as possible. They could then move back to the home key in their own time. The 
screen cleared 500ms after a response was made. The next trial started when the home 
key was pressed again. Therefore, the participants responded to the presentation of this 
single stimulus that required the same response across trials, thus allowing pre­
programming of the response.
On 50% of trials, before the solid white box (response stimulus) was presented an empty 
box (warning signal) was superimposed on the fixation cross. This occurred in a 
randomised manner. After a delay of sixteen hundred milliseconds this box was filled to 
become solid white, and this constituted the response stimulus. On 50% of trials there 
was no warning signal and the fixation cross was followed by a solid white box 
(response stimulus) immediately, in which case the participant was required to press the 
response key straight away. In all warned trials, the participants were instructed to make 
use of the warning signal and prepare themselves to respond to presentation of the 
response stimulus. Participants were also told to wait to respond until presentation of the 
response stimulus in order to discourage anticipatory responses. Figure 2(b) illustrates 
the computer screen at the differing stages over the unwarned and warned trials.
Handedness
All patients used their right hand to complete all trials of the SRT task, despite dominant 
handedness, in order to control for laterality of disease severity (i.e. PD symptoms are
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generally more severe on one side than the other). Controls also completed the SRT with 
their right hand in order to complete the protocol in an identical manner to patients.
(i) Unwarned Trial (Oms)
0 milliseconds
Imperative stimulus
(ii) Warned Trial (1600ms)
0 milliseconds
+
1600 milliseconds
Imperative stimulus
Figure 2(b) The computer screen images for unwarned (i) and warned trials (ii). 
Measurement o f initiation times and movement times
The time from presentation of the response stimulus to the release of the home key, i.e. 
the time between presentation of the stimulus and initiation of a response, was measured 
as the initiation time (IT). The time from release of the home key to pressing the
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response key i.e the time between initiating and executing a button press response, was 
measured as the movement time (MT). Both IT and MT were recorded by the computer 
to the nearest millisecond.
Reaction time and Reward
Each SRT test entailed four blocks of forty trials of the aforementioned task. Both DBS 
patients and healthy controls completed two sets of the four block SRT test with breaks 
in between. Other tasks were completed between the completion of one SRT test and the 
beginning of the second. The DBS patients completed one SRT test with stimulators on 
and the other with stimulators off. The order of this was counterbalanced between 
patients, with the first patient completing his first SRT “off’ stimulation and his second 
“on” stimulation and the next patient completing his first SRT “on” stimulation and his 
second “o ff’ stimulation etc. Counterbalancing the order of testing sought to address the 
issue of practice effects amongst the patients. Healthy controls also completed the SRT 
twice in order to control for potential practice effects.
To assess the impact of reward on motor performance, each task was performed with 
and without financial incentive. To avoid any biasing the participants were not told in 
advance that they would receive any reward. The participants completed two blocks of 
the SRT before they were told that they would receive a reward if they could speed up 
their reaction times. In blocks one and two participants received no reward for 
completing the task. In block three they received a 50 pence reward for every 10 
milliseconds they speeded up their reaction times. In block four participants received a 
£1 reward for every 5 milliseconds they speeded up their reaction times. On rewarded
53
trials, participants were informed of the potential reward for improved performance only 
before the beginning of that block i.e. participants were not informed of the increased 
financial reward of block four until they had completed block three. At the end of 
blocks 2 and 3, participants were provided with feedback and were told what their 
reaction times for that block had been.
Two incremental rewarded conditions were used in order to ascertain any differences 
both within the patient group (on stimulation vs off stimulation) and between the patient 
and control groups and to investigate whether each group, under differing reward 
conditions, could decrease their minimal reaction time speed, as found by other authors.
2.7.1.2 The CARROT Task
The Card Arranging Reward Responsitivity Objective Task (CARROT), (Powell et al, 
1996) measures the extent to which patients increase their speed of performance on a 
simple psycho-motor task when offered a small financial incentive. Therefore, the test is 
designed to index incentive reward responsiveness (Richardson, Powell & Curran,
2003). Participants were given a stack of cards, each with five single digits printed on 
them, one number in each comer and one number in the centre. The numbers on the 
cards were between one and nine, inclusive, and the cards have combination of all of 
those numbers. However, on each card a number 1 or a number 2 or a number 3 
appeared, and no combination of these numbers appeared on any one card. The aim of 
the task is to sort the cards as quickly as possible into stacks of 1, 2 and 3 contingent on 
whether one of the numbers on the card is 1, 2 or 3. The participants had four trials of 
sorting the cards as quickly as possible into stacks of 1, 2 and 3. On the first trial the
participants sorted 60 cards to measure baseline speed. On trials two, three and four the 
participants were given one hundred cards. Trials two and four measured unrewarded 
speed and trial three measures rewarded speed, i.e. speed of performance with 
expectation of financial incentive; namely lOp for every five cards correctly sorted. To 
avoid any biasing the participants were not told in advance that they would receive any 
reward. The participants completed two blocks of card sorting before they were told that 
they would receive a reward if they could speed up their performance.
2.7.2 Clinical Measures
The assessment of the patient and control groups was identical, with the exception of the 
Unified Parkinson’s Disease Rating Scale (UPRDS), an assessment of the severity of the 
motor symptoms in Parkinson’s disease, which was only completed for the patient 
group. To assess individual differences as well as possible between groups differences in 
mood, cognitive status and sensitivity to reward, the following additional measures were 
used.
Handedness
The Edinburgh Handedness Inventory (Oldfield et al, 1971) was used to assess the 
extent of right-handedness of each participant.
Beck depression inventory (BDI)
As depression may affect reaction times, the Beck Depression Inventory (BDI) was used 
to screen for the presence and extent of clinical depression for each participant. The 
BDI, (Beck, 1974) is a 21-item scale, which assess the affective, cognitive, behavioural
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and somatic aspects of depression. The scores range from 0 to 63, with higher scores 
indicating more severe self-reported depression. Scores above 18 are considered to 
indicate moderate to severe depression.
Marin Apathy Scale
As apathy may affect reaction times the presence and extent of apathy was assessed for 
each participant. The Marin Apathy Scale (Marin, 1990) is an 18-item scale that probes 
different aspects of apathy on a 0 -  3 scale. Some items are reversed scored. Scores 
range from 0 to 54 with higher scores indicating greater apathy. Scores above 14 are 
considered to reflect clinical levels of apathy.
Mini Mental State Examination (MMSE)
The Mini Mental State Examination (MMSE) (Folstein, Robinson, Folstein & McHugh, 
1985) is a brief screening instrument for cognitive impairment consisting of twenty 
items. The test is comprised of questions related to working memory, language, praxis 
orientation and attention (Lezak, 2004). Scores range from 0 to 30, with lower scores 
indicative of greater cognitive impairment. Scores below 25 are considered to reflect 
cognitive impairment.
Wechsler Abbreviated Scale of Intelligence (WASI)
The vocabulary and matrix reasoning subtests of the Wechsler Abbreviated Scale of 
Intelligence WASI (Wechsler, 1999) were used to obtain a measure of intelligence.
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Tridimensional Personality Questionnaire
The Tridimensional Personality Questionnaire (Cloninger at al, 1991) is a validated 100 
item questionnaire which assesses three dimensions of personality: responsiveness to 
reward, harm avoidance and novelty seeking, according to patient responses to specific 
statements. Responses to each statement are in a “yes”/ “no” format. The TPQ was used 
here in order to obtain an additional measure of responsiveness to reward, for the patient 
and control groups separately.
Unified Parkinson ’s disease Rating Scale (UPDRS)
The UPDRS is a clinical rating scale used to measure the severity of the motor 
symptoms of Parkinson’s disease. The UPDRS was completed on each patient at the 
time of their assessment while off medication and with DBS on and off. The scale 
includes the assessment of fourteen aspects of motor functions, including gait, balance, 
and the assessment of strength and dexterity of the hands, arms, legs and feet, each 
scored on a four-point scale, with a minimum score of zero maximum score of fifty-six. 
AH, was trained on this assessment by a neurologist (LMT). If patients had completed 
this assessment in clinic with neurologist IMT within three months of entering the study 
it was not repeated and clinic scores were used, as scores on this scale do not vary 
considerably within this time period.
2.8 Statistical analysis
Mixed model ANOVA’s were used to compare reaction times across unrewarded and 
rewarded conditions to determine the effect of DBS and reward. Group (PD patients and 
healthy controls) was used as the between groups variable and Stimulation (DBS on vs
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off or task repetition), Reward (presence vs absence) were used as the within subject 
repeated measures variables for analysis of the IT and MT data. Post-hoc Pairwise 
comparisons with Bonferroni correction were performed to further analyse the data 
shown as significant by the ANOVA. Paired samples t-tests were used to further 
compare the mean response times within groups over rewarded vs unrewarded 
conditions for significant interactions.
Paired samples t-tests were used to compare the mean scores on the CARROT card- 
sorting task to assess any differences in reward responsiveness across stimulation for 
patients and repetition for controls. Pearson correlations were used to determine the 
presence of any significant relationships between reward responsiveness, as measured by 
performance on the SRT and CARROT tasks and clinical measures relevant to 
motivation and reward.
RESULTS
The PD patients and healthy control groups did not differ significantly in terms of age, 
education, cognitive status or depression.
None of the patients or controls reached clinical caseness for depression (scores above 
18), as determined by responses to the Beck Depression Inventory (BDI). None of the 
patients or controls were cognitively impaired as determined by performance on the 
Mini Mental State Examination (MMSE) (scores below 25). The two groups differed 
significantly in terms of apathy (p = 0.019), with patients having a higher average apathy 
score than controls, and eight of the ten patients reached clinical caseness criteria (scores
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above 14) for apathy. However apathy was not a significant covariate between the 
groups (p = 0.475). The analysis was completed separately for Initiation times and 
Movement times.
The data was not normally distributed; however transformation was not possible as there 
were skews in both directions on different repeats of the same data. Therefore, 
parametric mixed model ANOVA’s were used to analyse the data, as there is no 
equivalent non-parametric test, and the ANOVA is robust to this problem. The 
conservative Bonferroni Correction was also used to ensure reliability of pairwise 
comparisons.
2.9 Initiation time
2.9.1 Effect o f Warning Signal on Initiation Time (IT)
To assess the effect of a warning signal on IT a mixed model ANOVA was completed 
with Group (PD vs controls) as the between subjects variable and DBS (on vs off for 
patients or time 1 vs 2 for controls) x Warning Signal (0 ms SRT vs 1600 ms SRT) x 
Reward (mean of rewarded blocks vs mean of unrewaded blocks) as the within subjects 
variables. The results of this analysis showed that, as expected, the main effect of 
warning signal was significant (F(l, 19 ) = 103.140; p= 0.001), such that IT with warned 
trials were significantly faster than unwarned trials across all groups and conditions; 
however none of the interactions between warning signal and the other variables were 
significant (p>0.05). Therefore, in subsequent analyses data were collapsed across the 
two warning intervals.
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2.9.2 Effect o f Group, Deep Brain Stimulation (DBS)/ Repetition and Reward, on 
Initiation Time (IT)
To assess the effects of Group, Stimulation/ Repetition and Reward on IT a mixed model 
ANOVA was completed with Group (PD vs controls) as the between subjects variable 
and DBS/Repetition (on vs off for patients or time 1 vs 2 for controls), Reward (mean of 
two rewarded blocks vs mean of two unrewarded blocks) as the within subject variables. 
The main effect of Group was significant (F(l, 19)= 31.19 p= 0.001), as the patients had 
slower IT across all conditions than the controls. The Stimulation/Repetition main effect 
was significant (F (1, 19) 4.96 p = 0.038). The main effect of Reward was significant 
(F(l,19) 21.46, p=0.001), indicating that across the two groups IT for the rewarded 
blocks were significantly faster than IT for the unrewarded blocks. The Group x 
DBS/Repetition interaction shown in Figure 2(c) approached significance (F(l, 19) 
3.277 p = 0.086). The DBS/Repetition x Reward (p=0.426) interaction, and the Group x 
Reward interaction (p=0.121) were not significant. The Group x DBS/Repetition x 
Reward interaction was also not significant (p=0.263).
To break down the significant main effects of stimulation and reward a number of post- 
hoc analyses were completed. Stimulation (DBS on vs off) had a significant effect on IT 
for the patients (p = 0.012). Repeated performance (time lvs 2) did not have a 
significant effect on IT for the controls (p = 0.766). Reward had a significant effect on 
IT for both patients (p = 0.001) and controls (p = 0.042).
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Figure 2(c) Illustrating the Groupx DBS/ Repetition interaction, which approached 
significance. Stimulation (DBS On/Off) on Initiation time in the patient group 
and Repetition (Time 1 vs Time 2) in the Control Group.
2.9.3 Effect o f Reward Magnitude on IT
To examine the effect of reward magnitude (50 p vs £1) on IT, IT for Block 3 (50 p 
reward per 10 ms IT speeding) and block 4 (£1 reward per 5 ms IT speeding) were 
compared across the two Groups (PD vs Controls) and for the two DBS/Repetition 
conditions (on vs off for patients, time 1 vs 2 for controls). A mixed model ANOVA 
was completed with Group (PD vs controls) as the between subjects variable and 
DBS/Repetition (on vs off or time 1 vs 2), and Reward Magnitude (50p vs £1) as the 
within subjects variables.
The main and interaction effects of Reward Magnitude were as follows. The main effect 
of reward magnitude was not significant (p = 0.515), indicating that across the two 
groups the IT for the high level reward block (£1) was not significantly faster than IT for
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the low level reward block (50p) (Figure 2(g). The DBS/Repetition x Reward Magnitude 
interaction approached significance (F(l, 19) = 3.645; p = 0.071). The Group x Reward 
Magnitude interaction (p = 0.234) was not significant. The Group x DBS/Repetition x 
Reward Magnitude interaction approached significance (F(l, 19) = 3.527; p=0.076). 
Figures 2(h) and 2(i) illustrate the interaction between Group, Stimulation/Repetition 
and Reward Magnitude, showing IT for rewarded and unrewarded blocks with DBS on 
vs off for the patients and for time 1 vs 2 for the controls.
2.9.4 Correlation of Initiation time and Clinical Measures
Pearson correlations were used to determine if unrewarded and rewarded initiation times 
and scores on the CARROT card-sorting test, indicating reward responsiveness 
correlated with the clinical measures relevant to motivation and reward responsiveness 
within the patient and controls groups. The analysis was conducted upon the groups 
separately. These measures were presence/absence of apathy, as determined by the 
scores on the Marin Apathy Scale. Correlation between reward dependence and 
unrewarded and rewarded initiation times and scores on the CARROT card-sorting test 
was determined by scores on the Tridimensional personality questionnaire (TPQ). The 
TPQ is a 100-item questionnaire that identifies personality traits including reward 
dependence. As multiple correlations were carried out the Bonferroni correction was 
used. No significant correlations were found, indicating that no significant relationships 
existed between initiation times, reward responsiveness and the presence/ absence of 
apathy.
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2.10 Movement Time
2.10.1 Effect o f Warning Signal on Movement Time (MT)
To assess the effect of a warning signal on MT a mixed model ANOVA was completed 
with Group (PD vs controls) as the between subjects variable and DBS (on vs off for 
patients or time 1 vs 2 for controls) x Warning Signal (0 ms SRT vs 1600 ms SRT) x 
Reward (mean of rewarded blocks vs mean of unrewaded blocks) as the within subjects 
variables. The results of this analysis showed that the main effect of warning signal was 
not significant (p= 0.085), such that MT with warned trials were not significantly faster 
than unwarned trials across all groups and conditions; however none of the interactions 
between warning signal and the other variables were significant (p>0.05). Therefore, in 
subsequent analyses data were collapsed across the two warning intervals.
2.10.2 Effect of  Deep Brain Stimulation/ Repetition, Reward and Group on Movement 
Time (MT)
To assess the effects of Group, Stimulation/ Repetition and Reward on MT a mixed 
model ANOVA was completed with Group (DBS patients and controls) as the between 
subjects variable and Stimulation/Repetition (on vs off or time 1 vs 2) and Reward 
(mean of unrewarded blocks vs mean of rewarded blocks) as the within subjects 
variables. MT was estimated as the time it took between the participant lifting his/her 
finger from the response key and pressing the target key upon presentation of the 
imperative stimulus.
The main effect of Group was significant (F(l, 19)= 38.019; p= 0.001), as the patients 
had slower MT across all conditions than the controls. The main effect of
63
Stimulation/Repetition was significant (F (1, 19) 38.66; p = 0.001). The main effect of 
Reward was not significant (F(l,19) = 1.68; p=0.210), indicating that across the two 
groups MT for the rewarded blocks was not significantly faster than MT for the 
unrewarded blocks. The Group x DBS/Repetition interaction, shown in figure 2(d) was 
significant (F(l, 19) = 38.78; p = 0.001), as patients had slower MT across all conditions 
than controls. The DBS/Repetition x Reward (F(l, 19) = 5.37; p = 0.032) interaction was 
significant. However, the Group x Reward (p=0.614) was not significant. The Group x 
DBS/Repetition x Reward interaction was significant (F(l,19)=7.41, p=0.015).
To break down the significant Group x DBS/Repetition x Reward interaction, a number 
of post-hoc analyses were completed. Stimulation (DBS on vs off) had a significant 
effect on MT for the patients (p = 0.001). Repeated performance did not have a 
significant effect on MT for the controls (p = 0.992). Reward did not have a significant 
effect on MT for the patients (p = 0.227) or controls (p = 0.576). For the patients, paired 
samples T-tests were completed to ascertain any differences in MT between DBS on vs 
off for the unrewarded and rewarded blocks separately. Patients’ MT was significantly 
faster with DBS on vs off for both the unrewarded block (t (9) = -6.435;p = 0.000) and 
for the rewarded block (t (9) -5.857; p = 0.001). Similarly, for the controls, paired 
samples T-tests were completed to ascertain any differences in MT between Repetition 
(time 1 vs 2) for the unrewarded and rewarded blocks separately. No significant effect of 
Repetition was found for the controls on either the unrewarded (p = 0.866) or rewarded 
(p = 0.870) blocks.
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Figure 2(d).Illustrates the significant Group x DBS/Repetition interaction. Stimulation/ 
Repetition on Movement times in patient and control group.
2.10.3 Effect of  Reward Magnitude on MT
To examine the effect of magnitude of reward (50 p vs £1) on MTs, MT for Block 3 
(50p reward per 10 ms IT speeding) and block 4 (£1 reward per 5 ms MT speeding) 
were compared across the two Groups (PD vs Controls) and for the two DBS/Repetition 
conditions (On vs off, time 1 vs 2). A mixed model ANOVA with Group (PD vs 
controls) as the between groups variable and DBS/Repetition (on vs off or time 1 vs 2), 
Rew ard magnitude (50p vs £1) as the within subject repeated measures variables.
The main and interaction effects of Reward Magnitude were as follows. The main effect 
of reward magnitude was not significant (p = 0.716), indicating that across the two 
groups the MT for the high level reward block (£1) was not significantly faster than MT 
for the low level reward block (50p). The main effect of Group was significant (F(l, 19)
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= 40.95; p= 0.000), as the patients had slower MT across all conditions than the controls. 
The Stimulation/Repetition main effect was significant (F (1, 19) 33.15 p = 0.001).
The Group x DBS/Repetition (F(l, 19) = 34.01; p = 0.001) interaction was significant, 
as patients had slower MT across all conditions than controls. The DBS/Repetition x 
Reward Magnitude (p = 0.632) interaction, the Group x Reward Magnitude (p = 0.227) 
interaction, and the Group x DBS/Repetition x Reward Magnitude interaction were not 
significant (p = 0.974).
2.10.4 Correlation of Movement time and Clinical Measures
Pearson correlations were used to determine if unrewarded and rewarded movement 
times and scores on the CARROT card-sorting test, indicating reward responsiveness 
correlated with the clinical measures relevant to motivation and reward responsiveness 
within the patient and controls groups. The analysis was conducted upon the groups 
separately. These measures were presence/absence of apathy, as determined by the 
scores on the Marin Apathy Scale. Correlation between reward dependence and 
unrewarded and rewarded movement times and scores on the CARROT card-sorting 
test was determined by scores on the Tridimensional personality questionnaire (TPQ). 
The TPQ is a 100-item questionnaire that identifies personality traits including reward 
dependence. As multiple correlations were carried out the Bonferroni correction was 
used. No significant correlations were found, indicating that no significant relationships 
existed between movement times, reward responsiveness and the presence/ absence of 
apathy.
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2.11 The CARROT task
No significant differences were found between patient performances “on” and “o ff’ 
stimulation (p=0.239) on the CARROT (Card arranging reward responsivity objective 
test), indicating that patients performance on this task was not significantly faster in the 
“on” stimulation condition compared with the “o ff’ stimulation condition. No significant 
differences were found between control performances at “time 1” and “time 2” 
(p=0.937), indicating that there were no significant effects of practice on controls’ 
performance on this task.
Discussion
The main findings of this study were:
• Patients initiation time showed a trend towards improvement and movement time 
(MT) was significantly faster on stimulation compared to off stimulation.
• The presence o f reward resulted in a significant speeding up of IT
• Stimulation did not significantly effect patients initiation time in response to
reward conditions to a greater extent than repetition effected controls initiation 
time in response to reward
• Stimulation did not effect patients performance on the CARROT card-sorting
task in response to reward conditions to a greater extent than repetition effected
controls performance on this task in response to reward.
• The presence o f a warning signal significantly improved patients initiation time.
Overall, patients IT and MT were slower than controls in all conditions, which is in 
accordance with the findings of other authors (de Frias, Dixon, Fisher & Camicioli, 
2007; Jahanshahi et al; 2001; Kutukcu et al, 1999; Mazzucchi et al, 1993).
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2.12 The Effect of Stimulation on Reaction Time
Hypothesis 1 STN DBS would speed up IT and MT for patients in the “on” stimulation condition as 
compared with the “o ff’ stimulation condition.
The results suggest a trend towards improvement in patients IT, and a significant 
improvement in patients MT in the “on” stimulation condition as compared with the 
“o ff’ stimulation condition. These findings are in accordance with the findings of other 
authors, who found improvement in response times under stimulation (Ellrichman et al, 
2008; Kumru et al, 2004; Temel et al, 2006). It should be noted that although only a 
trend towards statistical significance was found for improvement in IT, these results are 
reported in the context of a small sample size. No significant practice effects were seen 
for controls on IT or MT. This finding, and the counter-balanced design of the study, 
which was used to minimise the effects of practice, suggests that improvements seen in 
the patient sample were due to the effects of stimulation, as opposed to repeated 
performance of the IT tasks or practice.
However, although counter-balancing of patients was used to reduce practice effects, the 
analysis was conducted on the patients off stimulation and on stimulation assessments 
compared with the controls time 1 and time 2 respectively, thereby comparing both 
groups “worst” and “best” performances. Therefore, although the results suggest a trend 
towards improvement in patient response times as compared with the control group, this 
is complicated by the potential practice effects within the patient group. However, 
although this complicates the comparison of results between the patient and control 
groups, it was necessary to counter-balance in this manner, so as to decipher the effects 
of stimulation as opposed to the effects of practice had they not been counter-balanced.
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The results obtained, therefore, suggest that stimulation results in some improvement in 
initiation time, namely the premovement process. However, it appears that stimulation 
results in significant improvement in movement time, namely the motor process.
2.13 The Effect of Reward on Reaction Time
Hypothesis 2. The presence of reward would speed up IT in patients and controls
This hypothesis was supported as IT was improved in response to reward availability.
This finding supports the findings of other authors (Evarts et al, 1981; Mir et al, In
press). The main effect of reward on IT was significant across both groups, indicating a
general significant speeding of initiation times in response to reward. Further analysis
revealed significant speeding of initiation times in response to reward for each group
individually.
The results, therefore, show that the participants (both healthy controls and PD patients) 
could improve their initiation times in the presence of reward. This finding is in 
accordance with the concept of paradoxical kinesis and reflects the findings of Ballenger 
et al (2006) and Niv et al (2007), who found that healthy controls and PD patients 
respectively, could exceed their maximal self-determined speed of response in the 
context of external cues and urgent situations. Ballenger et al (2006) suggested that 
although paradoxical kinesis has been identified in PD, this phenomenon is not 
necessarily just a feature of disease but may be a general hallmark of the motor system, 
and these results support this.
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Paradoxical kinesis often occurs in response to urgent or dangerous stimuli, however, as 
the participants were not responding to dangerous stimuli but to monetary incentive, it 
may be concluded that the financial reward presented was a sufficient motivator to 
enable patients to speed their reaction times. This implicates the involvement of the 
Anterior Cingulate Circuit (ACC) which mediates motivation through neural pathways 
between the basal ganaglia and the frontal cortex (Bonelli & Cummings, 2007).
Studies highlight the role of the basal ganglia in reward related behaviours and implicate 
dopamine in reward anticipation and reward-related information processing and 
decision making (Arias-Carrion & Poppel, 2007; Berridge & Robinson, 2003; Nieoullon 
& Coquerel, 2003; Tricomi et al, 2004). It has been suggested that dopamine deficiency 
may cause aberrant decision-making (Niv et al, 2007). Contrary to the findings of other 
authors (de Frias et al, 2007; Kutukcu et al, 1999; Mazzucchi et al, 1993) who found that 
reaction times in PD are impaired relative to healthy controls, Mazzoni, Hristova, and 
Walker (2007) found that PD patients were generally as accurate and fast as controls on 
simple movement tasks. The authors concluded that dopamine deficiency in PD may 
cause aberrant implicit decision-making, resulting in increased sensitivity to the 
energetic demands of movement; namely that PD patients implicitly overestimate the 
energy required to perform a movement, which results in them generally performing 
below their level of ability (Mazzoni et al, 2007).
The current findings suggest that in the presence of a sufficiently motivating reward in 
the form of monetary incentive, movement initiation can be speeded up in PD, possibly 
through shifting the cost vs benefit balance in relation to the energetic demands of fast
70
movement. This improvement of speed of reaction is in accordance with the findings of 
Mazzoni et al (2007).
The current findings also suggest that there is a differentiation between the pre­
movement process and the execution of the movement in response to reward, as 
initiation times were affected by reward availability and movement times were not. 
Therefore the level of improvement appears to have occurred at the motor planning 
level, indicating the involvement of cognitive and motivational factors. This finding is in 
accordance with those of Mir et al (In press), who found greater improvement in IT of 
healthy controls than MT.
Brown and Pluck (2000) postulated a neuro-cognitive formulation of goal-directed 
behaviour; that is purposeful behaviour which is driven towards the attainment of a 
specific goal. Figure 3(a) illustrates this model. The current findings, therefore, may be 
understood in the context of this model, where motivational processes and properties 
influence the initiation of action across the groups. In the presence of a potential reward 
participants may select and prepare the relevant motor programmes prior to the 
presentation of the go stimulus in a more consistent fashion across trials. In PD patients 
this may, therefore, avoid the implicit energetic cost biases hypothesised by Mazzoni et 
al (2007). The SRT tasks entail the repeated response of one movement to one stimulus, 
thus allowing for the pre-programming of movement, which further supports this 
hypothesis.
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Figure 3(a). Pluck and Brown’s (2000) model of the processes involved in goal 
directed behaviour.
However, although presence of reward significantly improved IT, reward magnitude had 
no significant effect on IT, as patients and controls did not improve their IT in response 
to the second, higher level of reward. It may be the case, therefore, that have increased 
their IT at the first reward level, they reached their maximal or “ceiling” level of 
performance.
72
2.14 The Effect of Stimulation on Reward Responsiveness
Hypothesis 3. STN DBS would have a differential effect on reward responsiveness of patients IT over 
and above any change of IT with repeated performance in the control group
This hypothesis was not supported, as stimulation did not have a significant effect on 
patients responsiveness to reward in terms of improved IT. No practice effects on IT 
were seen for the controls. Therefore STN DBS did not have a differential effect on 
patients reward responsiveness in relation to control performance.
Hypothesis 4. STN DBS would have a differential effect on reward responsiveness of patients over and 
above any change of reward responsiveness with repeated performance in the control group, as 
assessed by performance on the CARROT card-sorting task.
This hypothesis was not supported, as stimulation did not have a significant effect on 
patients’ responsiveness to reward in terms of improved performance on the CARROT 
card-sorting task. No practice effects on repeated performance of this task were seen for 
the controls. Therefore STN DBS did not have a differential effect on patients reward 
responsiveness in relation to control performance.
These results suggests that, although STN DBS has effects on the motor frontal- 
subcortical circuit, stimulation does not influence the motivational frontal-subcortical 
circuit, the ACC, as no significant effects in reward responsiveness were found “on” 
stimulation. This suggests that STN DBS had no modulating effect on motivation in PD 
patients. This is contrary to the findings of other authors, some of whom found that STN 
DBS had detrimental effects on motivation, in the context of emergence or worsening of 
pre-existing apathy, which, in PD, is characterised by an isolated lack of motivation 
(Drapier et al, 2005; Funkiewiez et al, 2004; Saint-Cyr et al, 2000; Schupbach et al,
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2005; Temel et al, 2006). Other authors, however, have reported improvement in 
motivation after STN DBS (Contarino et al, 2006; Czemecki et al, 2005).
The current findings support the results of Castelli et al (2006), who found that apathy 
was stable after STN DBS, at 15 month follow-up, indicating that stimulation had no 
effect on motivation. The findings here may reflect that DBS has no genuine acute 
effects on motivation, however certain methodological issues may also account for this 
result, including small sample size and how representative the patient sample may be of 
the wider DBS-treated PD population. These issues will be discussed further below with 
reference to methodological issues.
The absence of any effect of stimulation on reward responsiveness can potentially 
inform us about the mechanism of action of DBS on the STN. It has been suggested that 
DBS of the STN acts a functional lesion in this area, thereby limiting the output of the 
STN. In a study of the effects of focal basal ganglia lesions on reward responsiveness 
Schmidt et al (2008) found that patients with basal ganglia lesions fail to differentiate 
between monetary incentives, and are therefore were less responsive to reward. If STN 
DBS operated as a functional lesion, it would be expected that reward responsiveness of 
PD patients with STN DBS to be impaired, as compared to controls, however this was 
not the case, as the results show that patients’ reward responsiveness was not impaired 
“on” stimulation. Therefore, the current findings suggest that DBS of the STN may 
operate in a manner other than as a functional lesion.
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2.15 The effect of warning signal on Reaction time
Hypothesis 5. The presence of a warning signal would improve patients initiation time.
Overall, patients initiation times benefited from a warning signal, which reflects the 
findings of other studies e.g.Jahanshahi et al, (1992). From the results obtained here, it is 
apparent that both patients and controls benefited from the presence of warning signal in 
ters of initiation time, however, the presence of a warning signal had no significant 
effect on movement time. This does not support the hypothesis that of Jahanshahi et al 
(1992), who suggested that patients with PD are selectively more reliant on a warning 
signal to maintain motor readiness. Therefore, it may be concluded that, generally, the 
presence of a warning signal allows participants, both PD and healthy controls, to 
prepare and maintain motor readiness.
2.16 Dopamine and Reaction Time
The patients in this study completed all tests off their dopaminergic medication and had 
been off their dopamine medication for an average of fifteen hours; yet they managed to 
improve their responses in the presence of reward. This is contrary to the findings of 
Czemecki et al (2002), who found that PD patients in the “off’ medication state had 
lower motivation in response to reward. However this finding supports those of 
Jahanshahi et al (1993), who found that reaction times in PD were not dopamine 
dependent, suggesting that slowness of IT may represent brain dysfunction rather than 
dopamine deficiency. The findings of this study implicate the involvement of non- 
dopaminergic circuits in reward related behaviours, as suggested by Lalonde & Botez- 
Marquard (1997).
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2.17 Apathy
As expected, the PD patients’ scores on the Marin Apathy Scale (Marin, 1990) were 
higher than controls. This supports the findings of other authors (e.g. Czemecki, 2002) 
and suggests that, even in the absence of depression or dementia, apathy is evident in 
PD, and can persist or newly present after STN DBS surgery. Although some authors 
have found stability of apathy (Castelli et al, 2006) and improvement of apathy after 
surgery (Czemecki et al, 2005), a number of authors have found apathy to newly present 
(Funkewiez et al, 2004; Saint-Cyr et al, 2000; Schupbach et al, 2005) or worsen (Drapier 
et al, 2005; Funkewiez et al, 2004) after STN DBS.
The high levels of apathy in this study may also be understood in the context of a 
chronic a-priori effect of DBS on the ACC and motivation. The ACC mediates 
motivation and is often impaired in PD, resulting in apathy syndromes (Pluck and 
Brown, 2000) and the influence of STN DBS on these circuits has been suggested by 
other authors (Czemecki et al, 2005). However, speculation about the origins of apathy 
in this patient sample is tentative, as the pre-operative apathy levels in the patient sample 
are unknown. The high levels of apathy found here may equally reflect pre-operative 
apathy, resulting from the PD disease process and related dopamine deficiency, as 
suggested by other authors, (Czemceki et al, 2002) as opposed to apathy arising from 
DBS.
2.18 Study limitations
There are a number of limitations to this study, due to restrictions of both time and 
patient population. One such limitation was the small sample size of the study.
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Recruitment difficulties were anticipated, as the patient population is small and the 
nature of the study necessitated an extensive period of time both off stimulation and off 
medication for the patients, which excluded a large number of potential patients who 
would not be able to tolerate their symptoms in this context. This also leads to the issue 
of generalisability of the results, which is another potential limitation to this study, as the 
patients included in the study had little tremor off stimulation and medication and so 
may not fully reflect the general population of DBS patients who present with more 
disabling motor symptoms. The issue of generalisability of the results also highlights the 
limitation of the levels of apathy found in the DBS sample. The majority of the patient 
sample in this study reached clinical caseness for apathy. This may reflect the influence 
of STN DBS on apathy; however the patients in this study may represent a sub-group of 
high-apathy PD patients. These limitations could be rectified with larger samples in 
future research.
The ethical issues arising around switching off of patients stimulators are another 
limitation of this study. In order to cause as little discomfort as possible to patients and 
to comply with the ethical considerations of the study patients were switched off 
stimulation for an average of approximately 45 minutes. Patients were relied on to 
determine when they were fully “o ff’ stimulation, usually waiting approximately ten 
minutes until commencing testing. Other studies however, had longer duration “off’ 
periods to ensure patients were off stimulation and that performance was not the result 
of any residual effects of stimulation. This was not possible here, however the current 
findings may have been more robust had this approach been implemented.
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It appears intuitive that money is an incentive and would therefore act as a reward, and 
in this study money appears to have been a motivating influence to speed response 
times. However, money may not have the same reward value to all individuals. The 
participants did not increase their IT at the second, higher reward level, which may have 
been the result of a “ceiling” effect; however it may be the case that the initial 
improvement in IT was not the result of reward-related behaviour but influenced by 
other factors. Therefore, a potential change I would make to this study would be the 
inclusion of different types of reward to assess any potential differential effects that may 
occur.
Patient handedness is another limitation of the study, as due to time limitations and 
patient eligibility to participate; left-handed patients were also included in the study. The 
ratio of right handed to left handed patients was 60:40. The necessity of using both right 
and left handed patients in the study may have had an impact on the results obtained, as 
all patients completed tests with their right hand. Differences in dominant handedness 
may complicate the interpretation of results, as participants who used their non­
dominant hands may have had slower reaction times on that basis. However, it was 
necessary for patients to only use their right hand as this controlled for any effects of 
disease laterality (i.e. PD symptoms are generally worse on one side than the other).
Practice effects are another issue which may also complicate the interpretation of the 
results obtained here. In order to control for any practice effects within the patient group 
a counter-balanced design was used, with one patient commencing testing “o ff’ 
stimulation and the next commencing “on” stimulation. The results of patients “off’ and
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“on” stimulation were analysed with the results of controls time 1 and time 2 
respectively. The results were analysed in this manner so as to assess the performance of 
both groups at their “worst” (off stimulation for patients/ time 1 for controls) and best 
(on stimulation for patients/ time 2 for controls). Therefore the results of half of these 
patients were from their second set of testing. Although this somewhat complicates the 
results, it was necessary to counterbalance the design in order to control for practice 
effects within group and it was considered that despite half of the patients potentially 
gaining from practice effects within group, this would not sufficiently influence their 
performance due to their level of disability off stimulation.
2.19 Summary and Conclusions
As anticipated, the results show that STN DBS improves IT and MT in PD patients. This 
finding and the improvements in motor symptoms, as examined by UPDRS assessment, 
indicate that STN DBS is an effective treatment for the motor symptoms found in 
advanced PD.
Participants improved their IT in the presence of reward, indicating that PD patients can 
increase their maximal speed of response in the presence of reward in the absence of 
dopaminergic medication. This points to the role of non-dopaminergic networks, for 
example the cholinergic system, in motivation/ reward responsiveness, as suggested by 
other authors.
STN DBS has overt effects on the motor frontal-subcortical circuit, with obvious results 
manifested in improvement in motor function. However, the potential effect of STN
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DBS on cognitive, affective and motivational circuits remains controversial. In this 
study, no significant effects of STN DBS on reward responsiveness were found, 
suggesting a lack of effect on upon the motivational ACC, as no behavioural changes 
attributable to DBS were seen in response to reward. However, the sample in this study 
was small and the majority of patients reported clinical levels of apathy, which may 
indicate that their performance represents a subgroup of apathetic PD patients, and so 
may not reflect reward responsiveness in the wider PD population who have undergone 
DBS.
Alternatively, the high levels of apathy seen in this group may result from chronic STN 
DBS or pre-operative apathy, as found by other authors. It was not possible to assess this 
here, as pre-operative apathy assessment was not carried out. The results indicate that 
future studies should consider a longitudinal approach to differentiate the potential acute 
effects of STN DBS on reward responsiveness and underlying motivational circuits and 
the longer-term effects of chronic STN DBS on apathy.
Future studies should, therefore, firstly ascertain the effects of STN DBS on the patient 
group through comparison of pre and post-operative apathy assessment and secondly to 
investigate the acute effects of STN DBS on reward responsiveness on the sub-groups of 
apathetic vs non-apathetic patients. Such an approach would also enable the 
differentiation of the effects of STN DBS on the differing frontal-subcortical circuits, in 
order to better understand the exact mechanism by which DBS may affect reward 
responsiveness, motivation, and apathy. The inclusion of an additional control group of 
medically treated patients with PD who have not undergone DBS surgery would have
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been a valuable addition to the study; however, it was not possible in this instance due to 
time limitations. This is an area of potential further development of the current research 
that could further inform us about the nature of reward responsiveness and apathy in PD 
across different treatment modalities and the mechanism of STN DBS on the frontal 
subcortical circuits.
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Part 3. Critical Appraisal
In this section the background of this study will be further discussed. The strengths 
and weaknesses of the study will also be discussed along with potential impact of 
weakness on the results and potential changes that could be made to overcome such 
limitations.
3.1 Background to this study
The current study developed from research focussing on reaction time deficits in 
Dystonia and reward responsivity of healthy controls. The thinking behind it arose from 
the impact of stimulation on the motivational circuits and neurotransmitters that mediate 
reward responsiveness in healthy people, which are often found to be impaired in 
Parkinson’s disease (PD). I was initially interested in this area because of its focus on 
the neuropsychological outcomes of a recently developed neurosurgical technique, 
namely DBS, and how these outcomes could further inform us about the functioning of 
underlying neural circuits. I have a long standing interest in the neuropsychological and 
neuropsychiatric side effects of surgery and the prospect of assessing the behavioural 
manifestations of, not only surgery, but electrical manipulation of specific brain areas 
presented a unique opportunity.
3.1.1 My experience of conducting this research
Conducting this study has been a rewarding and challenging experience. One of the 
many rewarding features of this research for me was that it allowed me to meet with 
patients who had undergone DBS surgery. I found that the patients involved were 
incredibly giving and selfless with their time and efforts despite undergoing difficult 
experiences, namely having their stimulators switched off, during the research.
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As Deep Brain Stimulation (DBS) is still in relative infancy and undergoing further 
development, the choices made regarding inclusion and exclusion criteria for the 
patients involved were not only based upon scientific principals but also had to take into 
account the ethical considerations that working with this group brought up. These ethical 
considerations continued to arise during the data collection period, as although the 
patients who were approached to participate consented freely to take part in the study 
often their participation brought up difficult realities for both the patients and for myself, 
namely witnessing the progression of their disease. This was one of the more personally 
challenging elements of conducting this study.
As aforementioned, the generosity of the patients involved was immense, as they 
contributed a significant amount of time and effort to participate. However, some of the 
patients involved had not had their stimulators switched off in some time, e.g.: six 
months to a year and some had not experienced this at all. On these occasions, the 
patients often commented on the how the disease had progressed. Although they were 
aware that the surgery did not halt the progression of their PD, it seemed that, upon 
switching off the stimulators, there was a realisation for some patients, that the disease 
was advancing further and that the surgery was only providing symptomatic relief of 
their an often aggressive disease. I found this difficult to witness, especially as this 
realisation seemed to occur in the context of the research. On the occasions when this 
happened, and when the patients wanted to discuss this, I listened to their concerns and 
feelings of uncertainty about their disease.
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This ethical issue was an unexpected element of the research process and one which I 
would take into consideration regarding future research. Although it was possible for me 
to discuss the patient’s concerns regarding the advancement of their disease, it seemed 
that when the realisation of their current stage of their PD occurred patients were quite 
taken aback. This left me with a feeling of responsibility, in terms of patient selection 
and after-care, which has subsequently effected how I would consider conducting the 
research in the future. It highlighted to me the necessity of understanding the patient’s 
psychological background prior to entry into the study and any difficulties they may 
have experienced with regard to adjustment to their physical health condition, as 
witnessing any advancement in their illness could impact on adjustment and any 
psychological disorder that may already be present.
Therefore, although the patients were selected in close collaboration with their 
consultants and nurses, I would consider this issue even further with these teams in the 
future. It would be important also, that not only patients with pre-existing psychological 
difficulties or health related adjustment or anxiety issues be considered, as conducting 
this study highlighted to me the importance of availability of psychological after-care for 
all patients, if required. I was not in a position to provide this in this situation; however, 
in terms of further research I consider this to be an important ethical matter.
Teamed with this experience, however, I also witnessed why the DBS patients were so 
generous with their time and willing to undergo discomfort for the sake of scientific 
study. This occurred successively from when I met with the first DBS patient;
90
witnessing him walk independently into the room and, upon switching off stimulation, 
witnessing him suffer disabling paralysis, spasm and tremor; the impact was overawing.
The experience of conducting this research has highlighted to me the importance of 
these procedures in the advancement of care for patients with PD, and the importance of 
neuropsychological and psychological assessment and intervention for patients, families 
and carers. It also highlighted the skill and innovation with which the surgeons work and 
the level of care and respect with which the medical and nursing care teams care for the 
patients. However, above all, the bravery of those patients and their families who live 
with PD, and those who have undergone DBS surgery and have allowed the 
advancement of surgical technique and scientific understanding from their treatment has 
been the most striking.
3.2 Research Approach (Choices made in research)
3.2.1 Inclusion/ exclusion criteria
The original inclusion criteria for patient participation in the study were:
Participants should be right handed and perform tasks using their right hand.
Surgical patients to be included will be minimum 6 months post surgery.
Only surgical patients with a good response to DBS and substantial improvement of 
clinical symptoms and post-surgery MRI evidence of correct positioning of the 
electrodes will be included.
Surgical patients will ideally have little tremor with stimulators off.
General good health other than PD.
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The exclusion criteria for both patients and controls in the study were:
Current or historical psychiatric illness.
The presence of any other neurological illness, both current and historical.
These criteria were chosen so as to ensure that the effects that were being studied were 
the result of STN DBS. These criteria maximised this by ensuring a homogenous patient 
sample, who gained sufficient post-operative relief from motor symptoms and therefore, 
in whom STN DBS was clinically successful; who were beyond the period when acute 
side-effects occur and did not have additional conditions that could influence the results. 
However, during the course of the research it was necessary to amend these criteria for 
patient inclusion, as due to the small patient population, the limited numbers of patients 
who could tolerate completing these tasks “o ff’ stimulation and the time restrictions of 
the study.
3.3 Methodological /  conceptual issues
3.3.1 Patient Handedness
On the basis of the aforementioned limitations, due to patient eligibility to participate in 
the study and time limitations, left-handed patients were also included in the study. The 
ratio of right handed to left handed patients was 60:40. The necessity of using both right 
and left handed patients in the study may have had an impact on the results obtained, as 
all patients completed tests with their right hand. Differences in dominant handedness 
may complicate the interpretation of results, as participants who used their non­
dominant hands may have had slower reaction times on that basis. However, it was
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necessary for patients to only use their right hand as this controlled for any effects of 
disease laterality (i.e. PD symptoms are generally worse on one side than the other).
3.3.2 Recruitment
As Deep Brain Stimulation (DBS) is still in relative infancy and undergoing further 
development, the choices made regarding inclusion and exclusion criteria for the patient 
involved were not only based upon scientific principals but also had to take into 
consideration the ethical considerations that working with this group brought up. As the 
numbers of patients who have received this surgery were relatively few, it was important 
for me to consult with my supervisor and her post-doctoral research fellow to consider 
who may be appropriate to approach for inclusion in the study. As a result of this 
surgery being a relatively recent surgical development of which little is known about the 
long term consequences, the patients who receive it are often asked to participate in 
research. Therefore during the course of the study it was decided that that my 
supervisor’s research fellow would initially approach the remainder of the identified 
patients to inform them of the study and enquire as to whether I could contact them to be 
involved. The research fellow was known to many of the patients, as she had also 
conducted their pre-operative clinical assessments, so this ensured that someone known 
to them would approach them in the first instance.
3.3.3 Clinical Measures
During the study it became apparent that the clinical measure questionnaires that were 
used to obtain demographic and clinical information about patients and controls were 
unnecessarily extending the length of the assessment. Many of the participants travelled
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long distances to be involved in the study and it was necessary, therefore, to use their 
time most effectively and as the PD patients were undergoing the off stimulation 
condition, it was important to not tire them out. Therefore during the course of the study 
it was necessary to begin posting the questionnaires out to patients prior to the study date 
for them to complete either the night prior to or on the morning of the study.
3.4 How my understanding of the phenomenon has changed
Throughout this research I have continued to develop my understanding of Parkinson’s 
disease, on a psychological and neuroscientific level. I have learnt much about the uses 
of reaction times in the assessment of brain function and the complex interaction 
between reward mechanisms and reaction times in this area.
In the context of this research I have had the opportunity to learn about the basal ganglia 
and neurosurgery in greater detail. Although daunting at first, this has given me a greater 
understanding of the role of psychology and neuropsychology in this area, both at a 
neuropsychological level in the assessment of preoperative and postoperative 
functioning and at the psychological level. This has highlighted to me the importance of 
ongoing psychological services for PD patients and their families, in relation to 
contemplating surgery, living with the disease and coping with the psychological 
symptoms that can often accompany it.
I have also taken much from this study in terms of learning more about the broader 
context of research and the political and systemic environment in which it takes place. I 
have developed a better understanding of the limitations but also opportunities of
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research, especially within the context of simultaneous clinical work. I have also gained 
more of an appreciation for the importance and application of psychological research in 
clinical settings, and specifically within neurological settings, where the patients 
psychological well being and that of the family is so closely tied to their neurological 
status.
3.5 Strengths and limitations of the research
In this study I was able to focus on STN DBS both on and off stimulation in a very rare 
group. Therefore, this study contributes to our understanding of a currently small, yet 
important field that will no doubt have broader impact in coming years, as surgical 
techniques are refined and applied to a wider PD population. Twelve patients 
participated, with ten successfully completing the study. Although this was a smaller 
number than initially intended, it is still a reasonable sample size relative to the patient 
population, especially considering the nature of the study, which entailed the patients 
enduring their worst “o f f ’ periods (both off medication and off stimulation), and the 
limited time available to complete the study.
However, there were limitations in this study also. One such limitation was the 
switching off of patients stimulators. In order to cause as little discomfort as possible to 
patients and to comply with the ethical considerations of the study patients were 
switched off stimulation for an average of approximately 45 minutes. I relied on the 
patients to determine when they were “o ff’ fully, usually waiting approximately ten 
minutes until commencing testing. Other studies however, had longer duration “o ff’ 
periods to ensure patients were off stimulation and that performance was not the result
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of any residual effects of stimulation e.g. Ellrichmann et al (2008) turned patients off 
stimulation one hour prior to the beginning of testing. This was not possible in this 
study, however the findings obtained here may have been more robust if we had 
implemented this approach.
3.5.1 Elements of study I would change
On the basis of the aforementioned weaknesses of this research, elements of the study I 
would change would include increasing the sample size and switching off the patients 
stimulators for a longer duration prior to testing. Although the patient sample obtained 
was reasonable I would increase the numbers of patients included in the sample if 
possible.
Other changes I would make to the study would be to use imaging techniques including 
functional magnetic resonance imaging (fMRI), or Positron Emission Tomgraphy (PET) 
in order to determine the specific areas of the basal ganglia and frontal cortex that were 
responding to reward and if this differed under stimulation conditions. This may enable 
us to draw more firm conclusions regarding the nature of the influence of stimulation on 
the frontal-subcortical circuits.
3.6 Clinical and scientific implications
The results found here indicate that STN DBS is a clinically successful technique that 
can ameliorate the debilitating motor symptoms of PD and adds to the vast literature to 
this effect. The results also indicate that PD patients can increase their maximal speed of 
response in the presence of reward, in the absence of dopaminergic medication, which
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has both clinical and scientific implications. Therefore, even in the context of dopamine 
deficiency patients were able to move faster in response to a motivating stimulus. This 
points to the role of non-dopaminergic networks, for example the cholinergic system, in 
motivation, reward responsiveness and movement, as suggested by other authors. 
Further research is required to assess the nature of the reward system in the context of 
dopamine deficiency, both at a neurotransmitter and neural circuit level. The results of 
this study also have implications for our understanding of the frontal-subcortical circuits 
and the influence of STN DBS on the function of these circuits. The implications will be 
discussed in the next section, with reference to future research
STN DBS is still a developing technique and there are vast clinical and scientific 
implications of this. The necessity of research into the non-motor side effects of the 
surgery are highlighted, as although controversial in the scientific literature, many 
patients and families report cognitive, functional and emotional difficulties arising after 
surgical intervention. This highlights the need for ongoing reciprocal research and 
clinical practice, in order to encourage ongoing research and assessment of the 
psychological effects of surgery which can be fed-back to surgical teams that are 
developing the techniques. In this manner, psychological research has an important role 
in the development of these techniques to the advantage of patient care and the 
advancement of scientific enquiry.
The high incidence of apathy in the patient group may reflect the influence of STN DBS 
on apathy in PD. However, it may also reflect apathy resulting from the original disease 
process. Whether the frequency of apathy in this sample were due to DBS or PD, it still
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remains that high numbers of patients with PD and STN DBS have clinical levels of 
apathy. This is an important clinical issue and highlights the need for assessment and 
intervention with both patients and families, as apathy is frequently reported as 
negatively effecting on quality of life and activities of daily living (Pluck & Brown, 
2002) and having significant negative impact on patients and families (Temel et al, 
2006).
3.6.1 Future directions for research
The results indicate that future studies are required to further investigate the influence of 
reward on motivational processes both in PD and healthy controls. This would allow for 
further investigation of the neural circuits that underlie motivational processes in health 
and disease. Further research on the influence of STN DBS on reward processes is also 
highlighted due to the high levels of apathy in the current patient sample, which may 
represent a sub-group of patients rather than reflecting the general population of PD who 
have undergone STN DBS. As well as focussing on reward-related tasks the importance 
of using both broad and focal neuropsychological tests is highlighted in order to 
differentiate the influence of reward on the frontal-subcortical circuits that underlie 
motivation and cognition. Tests of executive function should be included, to detect if 
cognitive function and the associated frontal-subcortical “executive” circuits may 
influence reward responsiveness. Future studies would benefit from a longditudinal 
approach, looking at pre and post-operative reward responsiveness and motivational/ 
apathy profiles, to determine if any differential effects of reward or stimulation exist 
within the DBS-treated PD population.
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Institute of Neurology
U C L  Sobell Research Department of
= = =  M otor Neuroscience and Movement Disorders
Professor Marjan Jahanshahi Institute of Neurology
Subject Information Sheet
Reaction Time Study in Movement Disorders
You are invited to participate in a research study conducted at the Institute of Neurology and the National 
Hospital for Neurology & Neurosurgery.
Aims of the study:
The aim of the study that you are asked to participate in is to find out the effect of Parkinson's disease on 
different reaction time tasks.
Parkinson’s disease is a movement disorder characterised by symptoms such as tremor, rigidity, and 
postural abnormality. We would like to investigate (i) whether and how the speed of movement initiation 
and execution is affected in Parkinson’s disease and (ii) the similarities and differences between the 
reaction time performance of three groups of participants (1) patients who have received surgery for 
treatment of Parkinson’s disease, (2) patients who take medication for the treatment of Parkinson’s 
disease and (3) healthy volunteers. Assessing healthy volunteers, like yourself, will help us to assess the 
nature and degree of slowing of reactions in these patient groups.
What we would like you to do during the study
We would like you to complete the tests described below. The purpose of each test will be explained to 
you, followed by a demonstration of what you have to do. The important thing is that you try to do your 
best on all the tests. On some tests such as the questionnaire measures of mood and motivation, there are 
no right or wrong answers and we are simply interested in your own current experiences. There will be 
two testing sessions, which will take place on the same day, once in the morning and once in the 
afternoon. Each session of testing will be about 2 hours with short breaks in between tests.
How will the study be performed?
We would like you to complete a number of relevant tests:
1. Measures of mood and motivation: You will be asked to complete several questionnaires to show us if 
you are experiencing any disturbance of mood as well as two questionnaires assessing motivation and 
personality.
2. Reaction time tasks: These tests will measure the speed with which you start and complete dimple 
movements under different conditions that are more or less attention-demanding. For example, in one 
reaction time task you are asked to press one of the four buttons that is indicated on the screen as quickly 
as you can.
3. Card sorting task: You are asked to sort a stack of cards as quickly as possible.
Your rights
Your participation in the study is entirely voluntary. You are free to decline to enter or to withdraw from 
the study at any time without having to give a reason. If you choose not to enter the study, or to withdraw 
once entered, this will in no way affect your future medical care.
Details about you will be stored on a computer during this research project. All information regarding 
your medical records will be treated as strictly confidential and will only be used for medical purposes. 
Your medical records may be inspected by competent authorities and properly authorised persons, but if 
any information is released this will be done so in coded form so that confidentiality is strictly 
maintained.
Participation in this study will in no way affect your legal rights.
This research project has been reviewed by the National Hospital for Neurology & Neurosurgery and the 
Institute of Neurology Ethics Committee.
Contacts:
If you are willing to help with this research study into how Parkinson’s disease may affect reaction times 
or would like to discuss this project further, please contact Andrea Higgins ( ) or Prof 
Maijan Jahanshahi at the Institute of Neurology on .
Prof M Jahanshahi Dr S Schneider Ms Andrea Higgins
i Institute of Neurology
XJCL Sobell Research Department of
M otor Neuroscience and Movement Disorders
Professor Marjan Jahanshahi Institute of Neurology
Email: m.Jahanshahi@ion.ucl.ac.uk Queen Square
Tel: (44) 020 7837 3611 ext 3055 London WC1N 3BG
Fax: (44) 020 7278 9836 (Box 146)
Subject Information Sheet
Version 3. 21th June 2006
Reaction Time and Deep Brain Stimulation Study
You are invited to participate in a research study conducted at the Institute of Neurology and the National 
Hospital for Neurology & Neurosurgery.
Aims of the study:
The aim of the study that you are asked to participate in is to compare reaction time in Parkinson's disease 
when the stimulators are on or temporarily switched off.
In an earlier study we have found that, compared to healthy subjects, reaction times in patients with 
Parkinson’s disease are slow compared to healthy individuals of the same age. In the proposed project, 
we would like to investigate whether and how the speed of movement initiation and execution in 
Parkinson’s disease is influenced by deep brain stimulation (DBS) of the subthalamic nucleus (STN) by 
comparing your performance on a series of reaction time tasks that measure of movement initiation and 
execution when the stimulators are on or temporarily switched off.
What we would like you to do during the study
We would like you to complete the tests described below. The purpose of each test will be explained to 
you, followed by a demonstration of what you have to do. The important thing is that you try to do your 
best on all the tests. On some tests such as the questionnaire measures of mood and motivation, there are 
no right or wrong answers and we are simply interested in your own current experiences. The testing will 
be about 2 Vi-3 hours with short breaks in between tests.
How will the study be performed?
We would like you to complete a number of relevant tests:
1. Measures of mood and motivation: You will be asked to complete several questionnaires to show us if 
you are experiencing any disturbance of mood as well as two questionnaires assessing motivation and 
personality.
2. Reaction time tasks: These tests will measure the speed with which you start and complete dimple 
movements under different conditions that are more or less attention-demanding. For example, in one 
reaction time task you are asked to press one of the four buttons that is indicated on the screen as quickly 
as you can.
3. Card sorting task: You are asked to sort a stack of cards as quickly as possible.
Why have you been chosen?
You have been invited to participate because you suffer from Parkinson’s disease, and you have been 
implanted with bilateral subthalamic nucleus stimulation. If you agree to participate you will be one of 
the 12 patients we hope to recruit into the study.
What are the risks and side effects of taking part in the study?
You may encounter some discomfort due to worsening of your parkinsonian symptoms when your 
stimulators are switched off for a maximum period of 45 to 60 minutes. Your symptoms should be well- 
controlled again when the stimulators are switched back on.
Your rights
Your participation in the study is entirely voluntary. You are free to decline to enter or to withdraw from 
the study at any time without having to give a reason. If you choose not to enter the study, or to withdraw 
once entered, this will in no way affect your future medical care.
Details about you will be stored on a computer during this research project. All information regarding 
your medical records will be treated as strictly confidential and will only be used for medical purposes. 
Your medical records may be inspected by competent authorities and properly authorised persons, but if 
any information is released this will be done so in coded form so that confidentiality is strictly 
maintained.
Participation in this study will in no way affect your legal rights.
This research project has been reviewed by the National Hospital for Neurology & Neurosurgery and the 
Institute of Neurology Ethics Committee.
Contacts:
If you are willing to help with this research study into how reaction times in movement disorders are 
affected or would like to discuss this project further, please contact Andrea Higgins ( ) or 
Professor Maijan Jahanshahi ) at the Institute of Neurology on .
Professor M Jahanshahi Ms Andrea Higgins
